<SEC-DOCUMENT>0001055726-21-000033.txt : 20210325
<SEC-HEADER>0001055726-21-000033.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325171709
ACCESSION NUMBER:		0001055726-21-000033
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		21773537

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>ino-2021xproxy.htm
<DESCRIPTION>DEF 14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie49dd27b85de418ab4eeaa7086da42bc_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SCHEDULE 14A</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proxy Statement Pursuant to Section&#160;14(a) of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934 (Amendment No.&#160;&#160;&#160;&#160;)</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by the Registrant </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by a Party other than the Registrant </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:480.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary Proxy Statement</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:480.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:480.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Proxy Statement</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:480.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Additional Materials</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:480.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting Material under &#167;240.14a-12</font></td></tr></table></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name of Registrant as Specified In Its Charter)</font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of Filing Fee (Check the appropriate box)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No fee required.</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&#160;0-11.</font></td></tr></table></div><div style="padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Title of each class of securities to which transaction applies&#58;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Aggregate number of securities to which transaction applies&#58;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined)&#58;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Proposed maximum aggregate value of transaction&#58;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Total fee paid&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:28.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee paid previously with preliminary materials.</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check box if any part of the fee is offset as provided by Exchange Act Rule&#160;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Amount Previously Paid&#58;</font></div><div style="margin-top:10pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Form, Schedule or Registration Statement No.&#58;</font></div><div style="margin-top:10pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Filing Party&#58;</font></div><div style="margin-top:10pt;padding-left:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">Date Filed&#58;</font></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">660 W. Germantown Pike, Suite&#160;110</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plymouth Meeting, Pennsylvania 19462</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders of Inovio Pharmaceuticals, Inc.&#58;</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notice is hereby given that Inovio Pharmaceuticals, Inc. will be holding its virtual Annual Meeting of Stockholders on May&#160;13, 2021, at 11&#58;00&#160;a.m., Eastern Time.  Online access to the meeting will begin at 11&#58;00 am Eastern Time. Stockholders will not be able to attend the meeting in person. </font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The virtual format of the 2021 Annual Meeting will provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. If you plan to attend the meeting, please check http&#58;&#47;&#47;ir.inovio.com&#47;investors for updates prior to the meeting date.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can attend the meeting by accessing www.virtualshareholdermeeting.com&#47;INO2021 and entering the 16-digit control number on the proxy card you previously received&#59; if you hold your shares in &#8220;street name&#8221; (i.e., through an account at a broker or other nominee), please follow your broker&#8217;s or nominee&#8217;s instructions you previously received to obtain your 16-digit control number or otherwise attend through the broker or nominee.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of stockholders of record will be available for examination by stockholders on the meeting website during the meeting. </font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notice of Annual Meeting of Stockholders and Proxy Statement, which describes the formal business to be conducted at the meeting, follows this letter.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After reading the Proxy Statement, please promptly mark, sign and return the enclosed proxy in the prepaid envelope (for mailing in the United States only) to assure that your shares will be represented at our Annual Meeting. Your shares cannot be voted unless you date, sign and return the enclosed proxy, vote your shares using the automated Internet or phone system or vote online at the meeting. Regardless of the number of shares you own, your careful consideration of, and vote on, the matters before our stockholders are important.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of our 2020 Annual Report is also enclosed.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you wish to submit a question, you may ask a question before the meeting beginning at 9&#58;00 am Eastern Time, on April 2, 2021, and until 11&#58;59 pm Eastern Time, on May 12, 2021. To submit a question, you may log into www.proxyvote.com and enter your 16-digit control number. Once past the login screen, click on &#8220;Question for Management,&#8221; type in your question, and click &#8220;Submit.&#8221; Only questions pertinent to meeting matters will be answered during the meeting, subject to time constraints.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you have not voted your shares prior to the meeting, you will be able to vote your shares electronically at the 2021 Annual Meeting by clicking &#8220;Vote Here&#8221; on the meeting website. Whether or not you plan to attend the meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials you previously received.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and management look forward to connecting with you at the Annual Meeting.</font></div><div style="margin-bottom:5pt;margin-top:17pt;padding-left:360pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.578%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Very truly yours,</font></div></td></tr><tr style="height:60pt"><td colspan="3" style="padding:0 1pt"><div><img alt="g696057g43r44a051a.jpg" src="g696057g43r44a051a.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:156px"></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-indent:317.25pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; March&#160;25, 2021 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">660 W. Germantown Pike, Suite&#160;110</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plymouth Meeting, Pennsylvania 19462</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO BE HELD MAY&#160;13, 2021 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders of Inovio Pharmaceuticals, Inc.&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You are invited to attend our 2021 Annual Meeting of Stockholders, which will be held virtually over the Internet, on May&#160;13, 2021, at 11&#58;00&#160;a.m., Eastern Time. </font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. To elect seven directors to hold office until our 2022 Annual Meeting of Stockholders and until their successors are elected and duly qualified. Our Board of Directors has nominated and recommends for election the following persons&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simon X. Benito</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">J. Joseph Kim, Ph.D.</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ann C. Miller, M.D.</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jay P. Shepard</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">David B. Weiner, Ph.D.</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wendy L. Yarno</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lota S. Zoth</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. To ratify the appointment by the Audit Committee of the Board of Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm for our fiscal year ending December&#160;31, 2021.</font></div><div style="margin-top:4.5pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. To approve, on a non-binding advisory basis, the compensation of our named executive officers we describe in our accompanying Proxy Statement. </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. To transact such other business as may properly come before the meeting. </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Board of Directors recommends a vote &#8220;for&#8221; each of the nominees and &#8220;for&#8221; proposals 2 and 3.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of record of our common stock and holders of record of our Series&#160;C Cumulative Convertible Preferred Stock at the close of business on March&#160;16, 2021, are entitled to notice of, and to vote at, this meeting and any adjournments thereof. For ten days prior to the meeting, a complete list of our stockholders of record on March&#160;16, 2021 will be available at our principal executive offices, during ordinary business hours, for examination by any stockholder for any purpose relating to the meeting. </font></div><div style="margin-bottom:5pt;margin-top:14pt;padding-left:360pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.578%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By order of the Board of Directors,</font></td></tr><tr style="height:60pt"><td colspan="3" style="padding:0 1pt"><div><img alt="g696057g43r44a051a.jpg" src="g696057g43r44a051a.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:156px"></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; March&#160;25, 2021 </font></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMPORTANT&#58; Please fill in, date, sign and promptly mail the enclosed proxy card in the accompanying postpaid envelope to assure that your shares are represented at the meeting. If you attend the meeting, you may choose to vote at the meeting even if you have previously sent in your proxy card.</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">660 W. Germantown Pike, Suite&#160;110</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plymouth Meeting, Pennsylvania 19462</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS</font></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors of Inovio Pharmaceuticals, Inc. (the &#8220;Board&#8221;) is soliciting proxies for use at the Annual Meeting of Stockholders to be held virtually over the internet, on May&#160;13, 2021 at 11&#58;00&#160;a.m. Eastern Time, or any adjournment thereof, for the purposes set forth in the accompanying Notice of Annual Meeting. This Proxy Statement is dated March&#160;25, 2021. We are mailing this Proxy Statement to our stockholders on or about April&#160;2, 2021. Unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Inovio,&#8221; and &#8220;Company&#8221; refer to Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Information</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Securities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Only stockholders of record as of the close of business on March&#160;16, 2021 will be entitled to vote at the meeting and any adjournment thereof. As of March&#160;16, 2021, we had the following outstanding&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">208,306,017 shares of common stock&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">9 shares of Series&#160;C Cumulative Convertible Preferred Stock, which are convertible into an aggregate of 3,309 shares of common stock.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may vote online at the meeting or using the automated Internet or phone system or by proxy. On the proposals presented in this Proxy Statement, each holder of shares of our&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">common stock is entitled to one vote for each share of stock held&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Series&#160;C Preferred Stock is entitled to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">votes for each share of Series&#160;C Preferred Stock held.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock and Series&#160;C Preferred Stock vote together as a single class in connection with each of Proposal Nos.&#160;1, 2 and 3. Our bylaws provide that one-third of all of the shares of the stock entitled to vote, whether present in person or represented by proxy, shall constitute a quorum for the transaction of business at the meeting. Thus, a quorum for this year&#8217;s Annual Meeting consists of 69,436,442 shares. Votes will be counted by the inspector of election appointed for the Annual Meeting. </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of a plurality of all of the votes cast at a meeting at which a quorum is present is necessary for the election of each of the nominees for director. Under plurality voting, the seven nominees receiving the largest number of votes cast (votes &#8220;For&#8221;) will be elected. For purposes of the election of directors, abstentions and broker non-votes will not be counted as votes cast and will have no effect on the result of the vote, although they will count toward the presence of a quorum. Broker non-votes occur when a broker holding a customer&#8217;s securities in street name does not vote on a particular proposal because the broker has not received voting instructions from the customer on certain matters for which the broker is required to have instructions in order to vote and lacks discretionary authority to vote the shares. If you do not provide specific voting instructions to your broker, the broker that holds your shares will not be authorized to vote on Proposal No. 1.  </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of the holders of a majority of the of the votes represented by shares present or represented by proxy and eligible to vote at the Annual Meeting is necessary for the approval of the Proposal Nos. 2 and 3 set forth in this Proxy Statement, as explained under each proposal. Abstentions will be counted as present for purposes of determining the presence of a quorum and could prevent the approval of a proposal because they do not count as affirmative votes. Broker non-votes will be counted as present for purposes of determining the presence of a quorum. If you do not provide specific voting instructions to your broker, the broker that holds your shares will not be authorized to vote on Proposal No. 3 but will be permitted to exercise discretionary authority to vote on Proposal No. 2.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solicitation of Proxies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We will bear the cost of soliciting proxies. In addition, we will solicit stockholders by mail, and will request banks and brokers, and other custodians, nominees and fiduciaries, to solicit their customers who have shares of our stock in the names of such persons and will reimburse them for their reasonable, out-of-pocket costs. We may use the services of our officers, directors, and others to solicit proxies, personally or by telephone, without additional compensation.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting of Proxies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If your shares are registered in your own name, you may vote by signing and mailing a completed proxy card or by voting via the Internet or by telephone. Instructions for voting via the Internet or by telephone are set forth on the enclosed proxy card. To vote by mailing a proxy card, sign and return the enclosed proxy card in the enclosed prepaid and addressed envelope, and your shares will be voted at the meeting in the manner you direct. In the event that you return a signed proxy card on which no directions are specified, your shares will be voted FOR each of the Board nominees (Proposal No.&#160;1)&#59; FOR ratification of the appointment of Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm for our fiscal year ending December&#160;31, 2021 (Proposal No.&#160;2)&#59; and FOR approval, on a non-binding advisory basis, of the resolution regarding compensation of our named executive officers we describe in this Proxy Statement&#160;(Proposal No.&#160;3), and in the discretion of the proxy holders as to any other matters that may properly come before the meeting. You may revoke or change a previously delivered proxy at any time before the meeting by delivering another proxy with a later date or by sending written notice of revocation of your proxy to our Secretary at our principal executive offices for receipt before the beginning of the meeting. You may also revoke your proxy by attending the meeting and voting as instructed. Attendance at the meeting will not in and of itself revoke a valid proxy that was previously delivered&#59; you must also vote at the meeting to do so.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If your shares are registered in the name of a bank or brokerage firm, you will receive instructions from the holder of record that must be followed in order for the record holder to vote the shares in accordance with your instructions. Many banks and brokerage firms have a process for their beneficial holders to provide instructions over the phone or via the Internet. If Internet or telephone voting is unavailable from your bank or brokerage firm, please complete and return the enclosed voting instruction card in the addressed, postage paid envelope provided.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the meeting, we intend to file a Form 8&#8209;K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery of Proxy Materials to Households.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Householding&#8221; is a program, approved by the Securities and Exchange Commission (the &#34;SEC&#34;), which allows companies and intermediaries such as banks or brokers to satisfy the delivery requirements for proxy statements and annual reports by delivering only one package of stockholder proxy material to any household at which two or more stockholders reside. If you and other residents at your mailing address own shares of our common stock in street name, your broker or bank may have notified you that your household will receive only one copy of our proxy materials. Once you have received notice from your broker that they will be &#8220;householding&#8221; materials to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate proxy statement, or if you are receiving multiple copies of the proxy statement and wish to receive only one, please notify your broker if your shares are held in a brokerage account. If you hold shares of our common stock in your own name as a holder of record, &#8220;householding&#8221; will not apply to your shares.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2021 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY&#160;13, 2021</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copies of this Proxy Statement and our 2020 Annual Report to Stockholders are also available online at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELECTION OF DIRECTORS</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board currently consists of seven members. There are seven nominees for director this year&#58; Simon X. Benito, J. Joseph Kim, Ph.D., Ann C. Miller, M.D., Jay P. Shepard, David B. Weiner, Ph.D., Wendy L. Yarno and Lota S. Zoth. Each of the nominees is currently one of our directors who was previously elected by our stockholders. </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If elected, the nominees will serve as directors until our Annual Meeting of Stockholders in 2022 and until their successors are elected and qualified. If a nominee declines to serve or becomes unavailable for any reason, the proxies may be voted for such substitute nominee as the proxy holders may designate.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Regarding Directors</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth below as to the nominees for director has been furnished to us by the nominees.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nominees for Election to Our Board</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present Position with the Company</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simon X. Benito</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim,&#160;Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann C. Miller, M.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay P. Shepard</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice-Chairman of the Board of Directors</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David B. Weiner, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Yarno</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lota S. Zoth</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simon X. Benito</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served on our Board since December 2003 and qualifies to serve on our Board as he brings to our Board formal accounting and financial training and expertise, significant public company board experience, senior management experience in the health care industry, and important industry contacts. Prior to his retirement, Mr.&#160;Benito had a successful and extensive career serving several multinational corporations in senior executive positions, including 25&#160;years at Merck&#160;&#38; Company,&#160;Inc. His most recent positions included Senior Vice President, Merck Vaccine Division&#59; Executive Vice President, Merck-Medco Managed Care&#59; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr.&#160;Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr.&#160;Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">J. Joseph Kim, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our President and Chief Executive Officer and as a director since 2009. Dr. Kim qualifies to serve on our Board given his broad scientific and industry experience and his experience as our Chief Executive Officer.  He was co-founder of our former subsidiary VGX Pharmaceuticals, Inc. (&#34;VGX&#34;), and also served as its President and Chief Executive Officer and a director from 2000 until its merger with us in 2009. He previously worked at Merck &#38; Company, Inc. developing vaccines. An immunologist by training, Dr. Kim holds an undergraduate degree from the Massachusetts Institute of Technology (&#34;MIT&#34;), a Ph.D. in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School at the University of Pennsylvania. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. MIT&#8217;s Technology Review magazine called him &#34;one of the world&#8217;s top innovators.&#34; Dr. Kim is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow&#8217;s healthcare system.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ann C. Miller, M.D. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">joined our Board in March 2019 and qualifies to serve on our Board as a result of her years of commercial experience in the biopharmaceutical industry and her clinical training. Dr. Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division.&#160;From 2009 to 2011, Dr. Miller served as Senior Vice President at Eisai Co., Ltd. leading&#160;the Primary Care and Specialty Business unit and then&#160;Pharmaceutical Services. Dr. Miller previously served in management roles in global and U.S. marketing at Amgen, Inc. for five years and in positions of increasing responsibility at Merck &#38; Co., Inc. over 16 years.&#160; Dr. Miller has served on the board of directors of the publicly traded companies Puma Biotechnology, Inc. since November 2019 and Allena Pharmaceuticals since October 2020.  Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in chemistry, summa cum laude, from Duke University.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jay P. Shepard </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">joined our Board in January 2020 and qualifies to serve on our Board as a result of his years of healthcare and financial experience. Mr. Shepard was President and Chief Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from May 2015 to January 2020 and has served as a member of its board of directors since 2013 and as its Chairman since January 2020. From 2012 until May 2015, Mr.&#160;Shepard was an Executive Partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr.&#160;Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr.&#160;Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel&#160;non-absorbed&#160;polymeric drugs for renal and metabolic disorders that was acquired by Amgen Inc. Mr.&#160;Shepard currently serves on the board of directors of Esperion Therapeutics, Inc. and Ironwood Pharmaceuticals, and serves as the Chairman of the Christopher&#160;&#38; Dana Reeve Foundation. Within the past five years, Mr.&#160;Shepard also served on the boards of directors of the public companies Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr.&#160;Shepard holds a B.S. in Business Administration from the University of Arizona.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">David B. Weiner, Ph.D. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">joined our Board in March 2016 and qualifies to serve on our Board as he is a recognized leader in immunology as well as in gene vaccines and therapy. Since 2016, Dr. Weiner has served as Executive Vice President and Director of the Vaccine Center at The Wistar Institute, the nation&#8217;s first independent biomedical research institute, which is also an NCI-designated Cancer Center and an international leader in cancer, immunology and infectious disease research. Dr. Weiner is also the W. W. Smith Charitable Trust Professor of Cancer Research at The Wistar Institute. Previously, Dr. Weiner was Professor of Pathology &#38; Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University&#8217;s Perelman School of Medicine.&#160;He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific American</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor and holder of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director&#8217;s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children&#8217;s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy.&#160;Dr. Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati and a B.S. in biology from SUNY at Stony Brook in Stony Brook, New York.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wendy L. Yarno </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">joined our Board in December 2017 and qualifies to serve on our Board as a result of her years of experience in the pharmaceutical industry. Ms. Yarno retired in September 2008 from Merck&#160;&#38; Company, Inc. following a&#160;26-year&#160;career in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer before she retired. Ms. Yarno also spent part of her career at Johnson &#38; Johnson, Inc. in commercial positions. Ms. Yarno currently serves on the boards of directors of the publicly traded companies Global Blood Therapeutics, Inc., Ideaya Biosciences, Inc. and Tarsus Pharmaceuticals. Within the last five years, Ms. Yarno served on the board of directors of MyoKardia, Inc., Alder Biopharmaceuticals, Inc., Aratana Therapeutics, Inc., Medivation, Inc. and St. Jude Medical, Inc. Ms. Yarno holds a B.S. in Business Administration from Portland State University and an M.B.A. from Temple University.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lota S. Zoth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">joined our Board in January 2019 and qualifies to serve on our Board as a result of her years of experience in senior financial roles in a variety of commercial-stage companies over a 35-year career. She currently serves as the chairman of the board of directors of the publicly traded biopharmaceutical company Zymeworks, Inc. and also serves on the board of directors of the publicly traded biopharmaceutical companies Lumos Pharma, Inc. and 89bio, Inc. Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.&#8217;s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms.&#160;Zoth served in financial executive roles at PSINet&#160;Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms.&#160;Zoth also served as an auditor at Ernst&#160;&#38; Young,&#160;LLP and is a Certified Public Accountant. Ms.&#160;Zoth holds a B.B.A. in accounting from Texas Tech University. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attendance at Board Meetings and Committee Meetings</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, our Board met eighteen times, the Audit Committee met six times, the Nomination and Corporate Governance Committee met four times and the Compensation Committee met seven times. Each director attended at least 75% of the aggregate number of meetings held by (i)&#160;our Board and (ii)&#160;those committees of our Board on which he or she served during the director&#8217;s tenure on the board or such committees.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of Our Board</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Corporate Governance Guidelines, we expect our directors to attend our Annual Meeting of Stockholders. All of our directors attended our 2020 Annual Meeting of Stockholders.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of the Audit Committee include retaining our independent registered public accounting firm, reviewing its independence, reviewing and approving the planned scope of our annual audit, reviewing and approving any fee arrangements with our independent registered public accounting firm, overseeing its audit work, reviewing and pre-approving any non-audit services that may be performed by it, reviewing the adequacy of accounting and financial controls, reviewing our critical accounting policies and reviewing and approving any related party transactions. The Audit Committee acts pursuant to a written charter that is available on our website at&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http&#58;&#47;&#47;media.corporate-ir.net&#47;media_files&#47;irol&#47;10&#47;105128&#47;corpGov&#47;AuditCommittee.pdf</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Audit Committee currently are Lota S. Zoth (Chair), Simon X. Benito and Ann C. Miller. Each member of the Audit Committee is independent under the Nasdaq listing standards. The Board has determined that Ms. Zoth and Mr.&#160;Benito are &#8220;audit committee financial experts&#8221; as defined under SEC regulations.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviews and approves the compensation and benefits of our executive officers, including the Chief Executive Officer and directors, oversees the administration of our stock option and employee benefits plans, and reviews general policy relating to compensation and benefits. The Compensation Committee may from time to time delegate duties or responsibilities to subcommittees or to one member of the Compensation Committee. The Compensation Committee acts pursuant to a written charter that is available on our website at&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http&#58;&#47;&#47;s22.q4cdn.com&#47;435600945&#47;files&#47;doc_downloads&#47;committee_composition&#47;Inovio-Amended-and-Restated-Compensation-Committee-Charter-November-2014_v001_j17o9d.pdf</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Compensation Committee currently are Wendy L. Yarno (Chair),  Ann C. Miller, Jay P. Shepard and Lota S. Zoth. Each member of the Compensation Committee is independent under the Nasdaq listing standards.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has engaged Radford, an independent compensation consultant, annually since 2016, to provide information on compensation trends and practices and to assist them in evaluating our executive compensation policy and programs. The analysis for fiscal year 2020 was used to determine appropriate levels of compensation for our executive officers and make recommendations regarding the amount and form of our executive and non-employee director compensation. The work of Radford did not raise any conflict of interest.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nomination and Corporate Governance Committee</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee identifies prospective candidates to serve on our Board, recommends nominees for election to our Board, develops and recommends Board member selection criteria, considers committee member qualification, recommends corporate governance principles to our Board, and provides oversight in the evaluation of our Board and each committee. The Nomination and Corporate Governance Committee acts pursuant to a written charter on our website at&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http&#58;&#47;&#47;s22.q4cdn.com&#47;435600945&#47;files&#47;doc_downloads&#47;committee_composition&#47;Inovio-Amended-and-Restated-Charter-of-the-Nomination-and-Corporate-Governance-Committee-November_v001_e50253.pdf</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Nomination and Corporate Governance Committee currently are Simon X. Benito (Chair), Jay P. Shepard and Wendy L. Yarno. Each member of the Nomination and Corporate Governance Committee is independent under the Nasdaq listing standards. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Nominations</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee evaluates and recommends to our Board director nominees for each election of directors. As stated in our Corporate Governance Guidelines, our Board believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements and having the highest personal integrity and ethics. The Board intends to consider factors such as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company&#8217;s stockholders. However, the Board retains the right to modify these qualifications from time to time.&#160;Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Board considers diversity, age, skills, and such other factors as it deems appropriate given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. The Nomination and Corporate Governance Committee and our Board believe that a diverse board leads to improved company performance by encouraging </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new ideas, expanding the knowledge base available to management and fostering a boardroom culture that promotes innovation and vigorous deliberation.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee believes that the continuing service of qualified incumbent directors promotes stability and continuity in the board room, while giving us the benefit of familiarity and insight into our affairs that directors have accumulated during their tenure, and therefore generally re-nominates incumbent directors who continue to satisfy the Committee&#8217;s criteria for membership on our Board. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of incumbent directors whose terms of office are set to expire, the Board reviews such directors&#8217; overall service to the Company during their term, including the number of meetings attended, level of participation, quality of performance, and any other relationships and transactions that might impair such directors&#8217; independence. In the case of new director candidates, the Board also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable&#160;Nasdaq&#160;listing standards, applicable SEC rules&#160;and regulations and the advice of counsel, if necessary.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee&#8217;s goal is to assemble a board that brings to us a variety of perspectives and skills, and sound business understanding and judgment, derived from high quality business, professional, governmental, community, scientific or educational experience. In doing so, the Nomination and Corporate Governance Committee also considers candidates with appropriate non-business backgrounds.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the foregoing factors, there are no stated minimum criteria for director nominees. However, the Nomination and Corporate Governance Committee may also consider such other factors as it may deem are in our best interests and the interests of our stockholders. The Nomination and Corporate Governance Committee does, however, recognize that under applicable regulatory requirements at least one member of our Board must meet the criteria for an &#8220;audit committee financial expert&#8221; as defined by SEC rules. The Nomination and Corporate Governance Committee also believes it appropriate for our Chief Executive Officer to participate as a member of our Board. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All directors and director nominees are required to submit a completed form of directors&#8217; and officers&#8217; questionnaire as part of the nominating process. The process may also include interviews and additional background and reference checks for non-incumbent nominees, at the discretion of the Nomination and Corporate Governance Committee.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee identifies nominees by first evaluating the current members of our Board who are willing to continue in service. Each year the Nomination and Corporate Governance Committee undertakes a board assessment process, which gathers data on the functioning of the Board and its committees and evaluates each member of the Board with respect to a number of attributes. The Committee considers for re-nomination current members of our Board with skills and experience that are relevant to our business balancing the value of continuity of service by existing members of our Board with that of obtaining a new perspective. If any member of our Board does not wish to continue in service, the Nomination and Corporate Governance Committee identifies the desired skills and experience of a new nominee in light of the criteria above. Current members of the Nomination and Corporate Governance Committee and our Board will be consulted for suggestions as to individuals meeting the criteria of the Nomination and Corporate Governance Committee. Research may also be performed to identify qualified individuals. If the Nomination and Corporate Governance Committee believes that our Board requires additional candidates for nomination, the Nomination and Corporate Governance Committee may explore alternative sources for identifying additional candidates. This may include engaging, as appropriate, a third party search firm to assist in identifying qualified candidates. </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nomination and Corporate Governance Committee will consider nominees recommended by stockholders. Our bylaws provide that nominations shall be made pursuant to timely notice in writing to our corporate secretary. To be timely, in the case of a stockholder seeking to have a nomination included in our proxy statement, a stockholder&#8217;s notice must be delivered to or mailed and received at our principal executive offices not less than 120&#160;days or more than 180&#160;days prior to the first anniversary of the date on which we first mailed our proxy materials (or, in the absence of proxy materials, our notice of meeting) for the previous year&#8217;s annual meeting of stockholders. However, if we did not hold an annual meeting the previous year, or if the date of the annual meeting is advanced more than 30&#160;days prior to or delayed by more than 30&#160;days after the anniversary of the preceding year&#8217;s annual meeting, then notice by the stockholder to be timely must be delivered to our corporate secretary at our principal executive offices not later than the close of business on the later of (i)&#160;the 90th&#160;day prior to such annual meeting or (ii)&#160;the 15th&#160;day following the day on which public announcement of the date of such meeting is first made. If the stockholder is not seeking inclusion of the nomination in our proxy statement, timely notice consists of a stockholder&#8217;s notice delivered to or mailed and received at our principal executive offices not less than 90&#160;days prior to the date of the annual meeting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholder&#8217;s notice relating to director nomination(s) shall set forth (a)&#160;as to each person whom the stockholder proposes to nominate for election or re-election as a director, (i)&#160;the name, age, business address and residence address of the person, (ii)&#160;the principal occupation or employment of the person, (iii)&#160;the class and number of shares of our capital stock which are beneficially owned by the person, and (iv)&#160;any other information relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant to Regulation&#160;14A under the Securities Exchange Act of 1934, or the Exchange Act&#59; (b)&#160;as to the stockholder giving the notice, (i)&#160;the name and record address of the stockholder, and (ii)&#160;the class and number of shares of our capital stock that are beneficially owned by the stockholder&#59; (c)&#160;as to the stockholder giving the notice and any Stockholder Associated Person, as described below, to the extent not set forth pursuant to the immediately preceding clause, whether and the extent to which any Relevant Hedge Transaction, as described below, has been entered into, and (d)&#160;as to the stockholder giving the notice and any Stockholder Associated Person, (1)&#160;whether and the extent to which any Derivative Instrument is directly or indirectly beneficially owned, (2)&#160;any rights to dividends on our shares owned beneficially by such stockholder that are separated or separable from the underlying shares, (3)&#160;any proportionate interest in our shares or Derivative Instruments, as described below, held, directly or indirectly, by a general or limited partnership in which such stockholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner and (4)&#160;any performance-related fees (other than an asset-based fee) that such stockholder is entitled to based on any increase or decrease in the value of our shares or Derivative Instruments, if any, as of the date of such notice, including without limitation any such interests held by members of such stockholder&#8217;s immediate family sharing the same household, which information shall be supplemented by such stockholder and beneficial owner, if any, not later than 10&#160;days after the record date for the meeting to disclose such ownership as of the record date. We may require any proposed nominee to furnish such other information as may reasonably be required by us to determine the eligibility of such proposed nominee to serve as a director.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of our bylaws&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A &#8220;Stockholder Associated Person&#8221; of any stockholder means (i)&#160;any person controlling or controlled by, directly or indirectly, or acting in concert with, such stockholder, (ii)&#160;any beneficial owner of shares of our stock owned of record or beneficially by such stockholder and (iii)&#160;any person controlling, controlled by or under common control with such Stockholder Associated Person&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A &#8220;Relevant Hedge Transaction&#8221; is any hedging or other transaction or series of transactions, or any other agreement, arrangement or understanding (including, but not limited to, any short position or any borrowing or lending of shares of stock), the effect or intent of which is to mitigate loss or increase profit to or manage the risk or benefit of stock price changes for, or to increase or decrease the voting power of, a stockholder with respect to any share of our stock&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Derivative Instrument&#8221; means any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of our shares, whether or not such instrument or right shall be subject to settlement in the underlying class or series of our capital stock or otherwise, or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of our shares.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance Guidelines, Code of Business Conduct and Ethics and Committee Charters</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate Governance Guidelines, our Code of Business Conduct and Ethics and the charters of the committees of our Board are available on our website, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Communications Policy</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has procedures in place designed to ensure effective communication among us, our stockholders, prospective investors and the public, including the dissemination of information on a regular and timely basis. Stockholders who want to communicate with our Board or any individual director can write to our Secretary at the following address&#58; 660 W. Germantown Pike, Suite&#160;110, Plymouth Meeting, Pennsylvania 19462. Your letter should indicate that you are one of our stockholders. Depending on the subject matter, management will&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Forward the communication to the director or directors to whom it is addressed&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Attempt to handle the inquiry directly, for example, where it is a request for information about us or it is a stock-related matter&#59; or</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Not forward the communication if it is primarily commercial in nature or if it relates to an improper or irrelevant topic.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership Structure</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board currently separates the roles of Chief Executive Officer and Chairman of the Board in recognition of the differences between the two roles. Our Chief Executive Officer is responsible for setting our strategic direction and our day-to-day leadership and performance, while the Chairman of the Board provides guidance to the Chief Executive Officer, works with the Chief Executive Officer in setting the agenda for Board meetings and presides over meetings of the full Board. However, our Board believes it should be able to freely select the Chairman of the Board based on criteria that it deems to be in our best interests and the interests of our stockholders, and therefore one person may, in the future, serve as both our Chief Executive Officer and Chairman of the Board.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of our Board are carried out by the full Board and, when delegated, by the Board committees. Each director participates in our major strategic and policy decisions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Role in Risk Management</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk oversight function of our Board is carried out by both the Board and the Audit Committee. Management prepares and presents an annual business plan to the Board, which identifies risks associated with our operations and is reviewed quarterly by the Board. As provided in its charter, the Audit Committee meets periodically with management to discuss major financial and operating risk exposures and the steps, guidelines and policies taken or implemented related to risk assessment and risk management. Matters of strategic risk are considered by our Board. Each quarter management reports to the Audit Committee on legal, finance, accounting and tax matters. Our Board is provided with reports on legal matters at least quarterly and on other matters related to risk oversight on an as needed basis.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics, which applies to all directors, officers and employees, including the principal executive officer, principal financial and accounting officer and controller. The purpose of the Code is to promote honest and ethical conduct. The Code of Business Conduct and Ethics and is available on our website and is also available in print, without charge, upon written request to our corporate secretary at 660 W. Germantown Pike, Suite&#160;110, Plymouth Meeting, Pennsylvania 19462. Any amendments to or waivers of the Code will be promptly posted on our website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or in a report on Form&#160;8-K, as required by applicable laws.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Member Independence</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that, except for Drs. Kim and Weiner, all of the nominees for election to our Board listed above are, and all other individuals who served as members of our Board in 2020 were, &#8220;independent&#8221; as independence is defined in the Nasdaq qualification standards. Dr.&#160;Kim was not considered independent because he is a current employee and Dr. Weiner was not considered independent because he currently serves as Chairman of the Scientific Advisory Board.   </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Board unanimously recommends that you vote &#8220;FOR&#8221; each nominee listed above. The proxy holders will vote your proxy in that manner unless you specify otherwise on the accompanying proxy card.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee Report</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee oversees our financial reporting process on behalf of our Board. Management has the primary responsibility for the financial statements, for maintaining effective internal control over financial reporting, and for assessing the effectiveness of internal control over financial reporting. In fulfilling its oversight responsibilities, the Audit Committee reviewed the audited consolidated financial statements in our annual report with management, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of disclosures in the financial statements.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee reviewed with Ernst&#160;&#38; Young&#160;LLP, who are responsible for expressing an opinion on the conformity of these audited consolidated financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of our accounting principles and such other matters as are required to be discussed with the Audit Committee by the applicable standards of the Public Company Accounting Oversight Board (United States) (&#34;PCAOB&#34;), the rules of the Securities and Exchange Commission (&#34;SEC&#34;) and other applicable regulations. In addition, the Audit Committee has discussed with Ernst&#160;&#38; Young&#160;LLP their independence from management and the Company, has received from Ernst&#160;&#38; Young&#160;LLP the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning independence, and has considered the compatibility of non-audit services with Ernst and Young&#8217;s independence.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee met with Ernst&#160;&#38; Young&#160;LLP to discuss the overall scope of their audit services, the results of the audit and reviews, its evaluation of our internal controls, including internal control over financial reporting, and the overall quality of our financial reporting. Ernst&#160;&#38; Young LLP, as our independent registered public accounting firm, also periodically updates the audit committee about new accounting developments and their potential impact on our reporting. The meetings with Ernst&#160;&#38; Young&#160;LLP were held with and without management present. The Audit Committee is not employed by us, nor does it provide any expert assurance or professional certification regarding our consolidated financial statements. The Audit Committee relies, without independent verification, on the accuracy and integrity of the information provided, and representations made, by management and our independent registered public accounting firm.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the reviews and discussions referred to above, the Audit Committee has recommended to our Board, and the Board has approved, that the audited consolidated financial statements and management&#8217;s assessment of the effectiveness of the Company&#8217;s internal control over financial reporting be included in our annual report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the SEC. The Audit Committee and the Board also have recommended the ratification of the appointment of Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm for 2021.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Audit Committee Report is not soliciting material, is not deemed to be filed with the SEC, and is not incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made by us before or after the date hereof, regardless of any general incorporation language in any such filing, except to the extent we specifically incorporate this material by reference into any such filing.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing report has been furnished by the Audit Committee.</font></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.122%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lota S. Zoth (Chair)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simon X. Benito</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann C. Miller, M.D.</font></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No member of the Compensation Committee is or was during the year ended December 31, 2020 an employee, or is or ever has been an officer of our Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Report</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has reviewed and discussed the matters contained under the title&#160;&#34;Compensation Discussion and Analysis&#34; in this Proxy Statement with our management and, based on such review and discussions we recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement. Portions of this Proxy Statement, including the Compensation Discussion and Analysis, have been incorporated by reference into the Company&#8217;s Annual Report on Form&#160;10-K for the Company&#8217;s fiscal year ended December&#160;31, 2020.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing report has been furnished by the Compensation Committee.</font></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:324pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.122%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Yarno (Chair)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann C. Miller, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay P. Shepard</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lota S. Zoth</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Directors</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Employee Director Compensation Program</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has approved cash compensation to be paid by the Company to its non-employee directors in the form of annual retainer payments. In November 2020 the Board approved an increase to the annual payment of the Board Chairperson and also approved the new position of Board Vice-chairperson as well as the compensation for that position.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual payments to non-employee directors are as follows&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairperson ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vice-chairperson ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Member ($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board of Directors</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nomination and Corporate Governance Committee</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance Committee</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Committee</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon their election or appointment to our Board, each of our non-employee directors is granted equity awards equivalent to stock options exercisable for 40,000 shares of our common stock, at the then fair market value pursuant to the terms of our 2016 Omnibus Incentive Plan, as amended, to be allocated as non-qualified stock options or restricted stock units (&#34;RSUs&#34;) at a ratio determined from time to time by our Board or its Compensation Committee, which the Compensation Committee has currently set at 1.56 stock options to 1 restricted stock unit. In addition, each non-employee director is automatically granted equity awards equivalent to a stock option to purchase up to 25,000 shares of our common stock if he or she remains on our Board on the date of each annual meeting of stockholders. Such awards will be allocated as non-qualified stock options and RSUs at a ratio determined from time to time by our Board or its Compensation Committee, which the Compensation Committee has currently set at 1.56 stock options to 1 restricted stock unit.  </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Non-Employee Director Option and Restricted Stock Unit Grants</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, each of our non-employee directors, Mr.&#160;Benito, Dr.&#160;Miller, Mr. Shepard, Dr. Weiner, Ms. Yarno and Ms. Zoth, received options to purchase 13,300 shares of our common stock exercisable at $13.65 per share. Upon joining the Board in January 2020, Mr. Shepard was granted options to purchase 20,000 shares of our common stock exercisable at $3.35 per share. Each of the foregoing option grants was made in accordance with our non-employee director compensation policy.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, each of our non-employee directors was also granted 8,700 RSUs and upon joining the Board in January 2020, Mr. Shepard was granted 12,821 RSUs. Each of the foregoing RSU grants was also made in accordance with our non-employee director compensation policy.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For his services as Chairman of our Scientific Advisory Board, in March 2020 Dr. Weiner was also granted options to purchase 60,000 shares of our common stock exercisable at $8.37 per share, and 35,000 RSUs.  </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation Table</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to non-employee director compensation during 2020.</font></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fees<br>Earned&#160;or<br>Paid in<br>Cash ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br>Awards<br>($)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Awards<br>($)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation ($)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br>($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simon X. Benito (3)</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,755&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,013&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,268&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angel Cabrera, Ph.D. (4)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann C. Miller, M.D. (5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,755&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay P. Shepard (6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,705&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,027&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David B. Weiner, Ph.D. (7)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,755&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971,314&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Yarno (8)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,755&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,013&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,768&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lota S. Zoth (9)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,755&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Represents the grant date fair value of RSU awards computed in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 718. See Note&#160;13 &#8220;Stockholders' Equity&#8221;, to our audited consolidated financial statements for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, for the assumptions made in determining stock compensation values.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Represents the grant date fair value of stock option awards computed in accordance with FASB ASC Topic 718. See Note&#160;13 &#8220;Stockholders' Equity&#8221;, to our audited consolidated financial statements for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, for the assumptions made in determining stock compensation values.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">At December&#160;31, 2020, Mr.&#160;Benito held options to purchase 107,050 shares of our common stock and 8,700 unvested RSUs.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Dr.&#160;Cabrera's term as a director concluded effective as of the conclusion of the 2020 Annual Meeting of Stockholders in May 2020.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">At December&#160;31, 2020, Dr. Miller held options to purchase 45,800 shares of our common stock and 17,247 unvested RSUs. </font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">At December&#160;31, 2020, Mr.&#160;Shepard held options to purchase 33,300 shares of our common stock and 21,521 unvested RSUs.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amounts presented in the &#8220;All Other Compensation&#8221; column for Dr. Weiner represent the grant date fair value of option and RSU grants to Dr. Weiner during the year for his service on our Scientific Advisory Board, calculated as described in footnotes (1) and (2) above.  At December 31, 2020, Dr. Weiner held options to purchase 515,550 shares of our common stock and 78,699 unvested RSUs.  </font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">At December&#160;31, 2020, Ms. Yarno held options to purchase 58,300 shares of our common stock and 8,700 unvested RSUs.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">At December&#160;31, 2020, Ms. Zoth held options to purchase 45,800 shares of our common stock and 16,880 unvested RSUs.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information as of March&#160;16, 2021 with respect to the beneficial ownership of our common stock by (i)&#160;each person known to us to be the beneficial owners of more than 5% of our common stock, (ii)&#160;each of our directors and nominees for director, (iii)&#160;each of our named executive officers and (iv)&#160;all of our directors and executive officers as a group.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership is determined in accordance with the rules of the SEC. In computing the number of shares beneficially owned by a stockholder and the percentage of ownership of that stockholder, shares of common stock underlying  options or RSUs held by that stockholder that are exercisable or issuable as the case may be, within 60&#160;days of March&#160;16, 2021 are included. Those shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other person. Each stockholder&#8217;s percentage of ownership in the following table is based upon shares of common stock outstanding as of March&#160;16, 2021. </font></div><div style="margin-bottom:5pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:61.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beneficial Owner of Shares of Common Stock(1)(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares of Common Stock Beneficially Owned</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of<br>Total<br>Shares&#160;of<br>Common&#160;Stock</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5% Stockholders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blackrock, Inc. (3)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,242,941&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Directors and Named Executive Officers&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D. (4)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simon X. Benito (5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,650&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann C. Miller, M.D. (6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,061&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay P. Shepard (7)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,274&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David B. Weiner, Ph.D. (8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,469&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Yarno (9)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,453&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lota S. Zoth (10)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,732&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies (11)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D. (12)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D. (13)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All current executive officers and directors as a group (10&#160;persons) (14)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,107,341&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 1%</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">This table is based upon information supplied by officers, directors and principal stockholders. Except as shown otherwise in the table, the address of each stockholder listed is in care of our principal executive offices at 660 W. Germantown Pike, Suite&#160;110, Plymouth Meeting, Pennsylvania 19462.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Except as otherwise indicated in the footnotes of this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or dispositive power with respect to securities. Applicable percentages are based on 208,306,017 shares of common stock outstanding on March&#160;16, 2021, adjusted as required by rules promulgated by the SEC.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">This information has been obtained from a Schedule 13G&#47;A filed on January 29, 2021 by BlackRock Inc. The principal business address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes 906,925 shares of common stock issuable pursuant to options exercisable within 60&#160;days of March&#160;16, 2021. Also includes (a) 816,527 shares held by a family limited partnership over which Dr. Kim holds voting and dispositive power, (b) 5,975 shares held by Dr. Kim&#8217;s spouse and (c) 100,871 shares held by Dr. Kim&#8217;s children.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes 98,300 shares of common stock issuable pursuant to options exercisable and 8,700 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consists of 40,800 shares of common stock issuable pursuant to options exercisable and 12,974 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consists of 23,300 shares of common stock issuable pursuant to options exercisable and 8,700 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes 485,550 shares of common stock issuable pursuant to options exercisable and 8,700 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes 58,300 shares of common stock issuable pursuant to options exercisable and 8,700 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Includes 40,800 shares of common stock issuable pursuant to options exercisable and 8,700 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Includes 565,584 shares of common stock issuable pursuant to options exercisable within 60&#160;days of March&#160;16, 2021. Also includes 4,500 shares held by Mr. Kies&#8217;s spouse.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Includes 299,359 shares of common stock issuable pursuant to options exercisable within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Consists of 76,209 shares of common stock issuable pursuant to options exercisable and 16,667 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021. </font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Includes 2,595,127 shares of common stock issuable pursuant to options exercisable and 73,141 shares of common stock underlying RSUs which will vest within 60&#160;days of March&#160;16, 2021.</font></div><div style="margin-top:6pt;text-indent:-9pt"><font><br></font></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_19"></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS AND OTHER INFORMATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Executive Officers</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information as to persons currently serving as our executive officers, including their ages as of March&#160;25, 2021&#58;</font></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For biographical information regarding Dr.&#160;Kim, see &#8220;Proposal 1&#8212;Election of Directors.&#8221;</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Peter D. Kies&#8212;Chief Financial Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr.&#160;Kies has been employed as our Chief Financial Officer since 2002. From 1996 until joining us, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst&#160;&#38; Young&#160;LLP. Mr.&#160;Kies holds a B.S. in Business Administration from United States International University in San Diego, California.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Laurent M. Humeau, Ph.D.&#8212;Chief Scientific Officer. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dr. Humeau has served as our Chief Scientific Officer since March 2019, having previously served as our Vice President and then Senior Vice President of Research and Development beginning in January 2014. Prior to joining us, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon Corporation and previously served in a variety of roles, including Chief Scientific Officer and Vice President of Research and Development, at VIRxSYS Corporation. Dr. Humeau performed his post-doctoral formation at the University of California, San Francisco. He holds a Ph.D., summa cum laude, from Denis Diderot University (Paris 7, France) and a M.S. degree in Biology from Pierre &#38; Marie Curie University (Paris 6, France).</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jacqueline E. Shea, Ph.D.&#8212;Chief Operating Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr. Shea has served as our Chief Operating Officer since March 2019. Prior to joining us, Dr. Shea served as Chief Executive Officer of Aeras, a nonprofit organization developing tuberculosis vaccines, from August 2015 to December 2018, and as its Chief Operating Officer from April 2014 to August 2015. Dr.&#160;Shea previously served as Vice President of Business Development, Europe for Emergent BioSolutions Inc. from May 2013 to March 2014, having previously served as Senior Director of Business Development for Emergent BioSolutions from 2005 to 2008.  She was Vice President and General Manager of The Oxford-Emergent Tuberculosis Consortium, a global health joint venture formed between Oxford University and Emergent BioSolutions, from 2008 to 2013. She started her career as a post-doctoral researcher at Imperial College, London. Dr. Shea holds a Ph.D. from the National Institute for Medical Research, London, and a B.Sc. Hons. in Applied Biology from the University of Bath, U.K.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No family relationships exist between any of our directors or executive officers.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font><br></font></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_22"></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPENSATION DISCUSSION AND ANALYSIS</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (&#34;HPV&#34;), cancer, and infectious diseases. The success of development companies is significantly influenced by the quality and motivation of their work force. Our compensation programs are straightforward and generally do not change materially from year to year&#59; however, for the first time our 2020 program included performance-based equity in the form of performance-based restricted stock units (&#34;PSUs&#34;). The core principle of our compensation for executive officers continues to be a strong pay-for-performance structure that ties a significant portion of each executive officer&#8217;s compensation to corporate performance. We seek to provide a competitive total compensation opportunity for our executive management team through a combination of base salary, cash incentive bonuses, long-term equity incentive compensation and benefit programs. Our pay-for-performance structure drives the amount of pay that is actually realized.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Compensation Discussion and Analysis describes our compensation objectives, our executive compensation process and our policies and actions with respect to each compensation element. We describe the rationale for compensation decisions made in 2020 with respect to the following named executive officers for the fiscal year ended December 31, 2020&#58;</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</font></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other persons served as executive officers of our company during the year ended December 31, 2020.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">2020 Highlights</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key 2020 Company highlights included&#58;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced REVEAL 1 (cervical dysplasia) and REVEAL 2 (confirmatory study) Phase 3 trials for product candidate VGX-3100&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented efficacy data for the VIN and AIN (vulvar and anal dysplasia) Phase 2 trials for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VGX-3100&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented efficacy data (OS18) for product candidate INO-5401 + cemiplimab in glioblastoma multiform (GBM) patients&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Advanced the recurrent respiratory papillomatosis (RRP) program (product candidate INO-3701), including dosing of first patient in 2020&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced INNOVATE trial for product candidate INO-4800 including completion of Phase 1 and initiation of Phase 2 trials in 2020&#59; </font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced infectious disease vaccine programs for Lassa fever (INO-4500) and MERS (INO-4700)&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Published over 20 peer-reviewed publications and filed multiple patents&#59;</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raised additional funding through a combination of corporate licensing and partnering, non-dilutive grants and equity financing&#59; and</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determined to maintain our incentive programs, with no changes to the design, metrics or targets and no discretion applied to performance results or payouts as a result of the impacts of COVID-19.</font></div><div style="margin-top:5pt;padding-left:9pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Key Aspects of 2020 Executive Compensation&#58; Strong Performance Orientation</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.65pt">2020 CEO Compensation&#58; Target Total Compensation 91% Variable and At-Risk&#59; Long-Term Incentive Equity 50% Performance-Based PSUs</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 91% of our Chief Executive Officer&#8217;s 2020 target total compensation for the year ended December 31, 2020* was variable and at-risk, and 50% of the long-term incentive equity component* was performance-based PSUs. The PSUs, which the Compensation Committee introduced in 2020, are subject to clinical, funding, manufacturing and regulatory </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goals tied to our strategy, and only vest if such goals with respect to INO-4800, our COVID-19 vaccine candidate, are achieved (please see below). The other 50% of the long-term incentive equity was time-based RSUs, which vest ratably over three years.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We place significant emphasis on variable, performance-based incentive compensation that focuses on our executives&#8217; efforts to deliver both short-term and long-term value for our stockholders without encouraging excessive risk-taking. We accomplish this by placing a substantial portion of our executive officers&#8217; total compensation &#8220;at-risk.&#8221; We consider compensation to be &#8220;at-risk&#8221; if it is subject to achievement of meaningful pre-set, objective goals, such as in our annual incentive program, or if it depends on the stock price, as in our long-term incentive program.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphic below illustrates the mix of fixed base salary, annual incentive and long-term target incentive compensation* we provided to our CEO for the year ended December 31, 2020 and the high proportion that is variable and at-risk.</font></div><div style="text-indent:22.5pt"><font><br></font></div><div style="text-align:center;text-indent:22.5pt"><img alt="image1.jpg" src="image1.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:470px"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*The Compensation Committee set the target value of the PSUs granted to the CEO at the same amount as the target value of the RSUs granted to the CEO, such that there was an approximately equal 50&#47;50 split in the long-term incentive equity between performance-based and time-based. However, for the PSUs, no compensation grant date fair value has been recorded for accounting purposes or included in the tables below, as the underlying clinical and regulatory performance conditions in the PSUs were not deemed to be probable of achievement as of the grant date, in accordance with the accounting rules specified by FASB ASC Topic 718.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance-based metrics and the proportion of total compensation that was variable and at-risk enhanced the link between pay and performance for the CEO and strengthened the alignment of the interests of the CEO with those of the Company and its stockholders.</font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.65pt">Performance-Based PSUs&#58; Rigorous Milestone Goals for COVID-19 Vaccine Candidate</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 PSUs have performance conditions related to the development and commercialization of INO-4800, our vaccine candidate for COVID-19. </font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the PSUs will only vest, if at all, upon the achievement of&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">full enrollment in our planned Phase 2&#47;3 trial of INO-4800&#59; </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">non-dilutive, third-party funding for clinical development and manufacturing of INO-4800&#59; </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">manufacture of 100 million doses of INO-4800 and a specified number of delivery devices&#59; and </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">U.S. FDA approval, with no more than a specified number of other COVID-19 vaccines having previously received such approval.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The target achievement date for each of the goals is within three years.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a goal has been achieved and the respective number of shares underlying PSUs have been earned, 50% of the underlying shares earned will vest on the date of achievement, and the remaining 50% of the underlying shares earned will vest one year thereafter, subject to the executive officer&#8217;s continued employment with us through such date</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.65pt">Annual Cash Incentive&#58; Rigorous, Pre-Set Clinical, Regulatory and Corporate Goals, Strong Performance Achievement and Annual Incentive Plan Payouts Reflecting Pay for Performance Alignment</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the beginning of 2020, we established annual cash incentive plan goals that management and the Compensation Committee considered rigorous, aggressive and challenging, attainable only with strong performance, and that took into account relevant opportunities and risks.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed below, the objective, measurable goals fall into five categories&#58; </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">Advance the preparation of a Biologics License Application and commercialization&#58; VGX-3100 (HPV-associated diseases)&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">Advance the Orphan Disease Program&#58; RRP </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">Advance the oncology and orphan disease programs</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">Advance the infectious disease programs (including MERS and Lassa)</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.89pt">Other corporate objectives (including financing and business development)</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and regulatory categories require enrollment, trials and other development activities for new product candidates. The corporate objectives involved raising capital and developing strategic plans.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee set challenging targets and evaluated performance achievement relative to the goals. Despite the impacts of COVID-19 in 2020, no adjustments were made to our annual incentive performance achievement as a result. Based on achievement of the foregoing components, actual bonus payouts to our named executive officers for 2020 performance were at 110% of the targeted amounts. </font></div><div style="margin-top:5pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9.65pt">Peer Group&#58; Assessed and Updated Peer Group to Reflect Then-Current Market Capitalization </font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Compensation Committee reassesses the group of peer companies used as a reference point for evaluating executive compensation. In connection with determining the compensation of the CEO and other executive officers, the Compensation Committee conducted a review of our peer group to ensure its continued appropriateness.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the then-decrease in our market capitalization, the Compensation Committee revised the peer group selection criteria for company size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to reference a lower market capitalization range than the previous year ($100 million to $900 million), which resulted in the removal of six companies and the addition of six new companies, as compared to our 2019 peer group.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with best practices for corporate governance, the Compensation Committee has committed to review the peer group annually.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Executive Compensation Program</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Program Objectives</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design our executive compensation program to achieve the following objectives&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Motivate and reward executives whose knowledge, skills and performance are essential to our success&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Align the performance of our executives and the interests of our stockholders&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recruit and retain executive talent&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Support the corporate business strategy and business plan by rewarding achievement based on our expectations for results and attainment of short-term and long-term goals by our executives.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Say-on-Pay Vote</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our annual meeting of stockholders in 2020, approximately 87% of the votes cast on the say-on-pay proposal supported the proposal. Our Board and our Compensation Committee value the opinions of our stockholders, and we believe that it is important for our stockholders to have an opportunity to vote on this proposal annually. In addition to our annual advisory vote on executive compensation, we are committed to ongoing engagement with our stockholders on executive compensation and corporate governance issues.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee has considered the results of the advisory vote in the context of our overall compensation philosophy, policies and decisions. Our Compensation Committee believes that the 2020 stockholder vote endorsed our compensation philosophy and the decisions we made for 2019. After discussing the levels of support in past years in favor of the proposals, and considering the Compensation Committee&#8217;s continued use of the measures we adopted in response to </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previous advisory votes to further align management and stockholder interests, including stock ownership guidelines, our Compensation Committee decided to generally maintain a consistent course for 2020 compensation decisions, with the addition of performance-based equity in the form of PSUs.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Process</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">Role of the Compensation Committee</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of our Board has the primary responsibility for determining compensation of our executives. Our Board has determined that each member of our Compensation Committee is &#8220;independent&#8221; as that term is defined by applicable Nasdaq rules, is an &#8220;outside director&#8221; as defined in Section&#160;162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) (to the extent necessary to comply with the &#8220;performance-based compensation&#8221; exception from Section 162(m) of the Code prior to its repeal by the Tax Cuts and Jobs Act for taxable years beginning after December 31, 2017 or the related transition relief discussed below) and is a &#8220;non-employee&#8221; director as defined under Section&#160;16 of the Exchange Act.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee determines all compensation matters for our named executive officers, including base salary, bonuses, and equity compensation. Utilizing input from our Chief Executive Officer as well as that of independent compensation consultants as needed, the Compensation Committee makes an independent decision on compensation for each executive. The Compensation Committee also oversees the Chief Executive Officer and other senior officers in making compensation determinations of our non-executive staff. The Compensation Committee assesses performance on a number of subjective and objective factors, including the achievement of company and individual performance goals.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making decisions regarding executive compensation, our Compensation Committee considers, among other things&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Measurable accomplishments and performance of the Company in meeting the annual objectives&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Past compensation levels of each executive and the executives as a group&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consistency of current compensation with previous compensation decisions and benchmarks&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compensation paid to comparable positions at peer companies&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Existing levels of stock and stock option ownership among our executives, previous stock option grants and vesting schedules to ensure executive retention and alignment with stockholder interests&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management recommendations&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General trends in executive compensation.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee conducts an annual review of the Chief Executive Officer&#8217;s performance and reports its evaluation to the Board. The Board reviews the Compensation Committee&#8217;s evaluation and recommendation and also evaluates the Chief Executive Officer&#8217;s performance according to the goals and objectives established periodically by the full Board. This review serves as the basis for the recommendation of the Compensation Committee on Chief Executive Officer compensation. The Chief Executive Officer does not play any role with respect to any matter affecting his own compensation and is not present when the Compensation Committee discusses and formulates the compensation recommendation.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Role of the Independent Compensation Consultant</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee recognizes that there is value in procuring independent, objective expertise and counsel in connection with fulfilling its duties and has the authority to retain an independent compensation consultant to assist it in carrying out its responsibilities and duties. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has the authority to engage advisers to assist the committee in carrying out its duties. The Compensation Committee has engaged Radford, which is part of the Rewards Solutions practice at Aon plc, an independent compensation consultant, to provide information on compensation trends and practices and to assist in evaluating our executive compensation policy and programs. The Compensation Committee engaged Radford in 2020 for compensation consulting services. To facilitate the Compensation Committee&#8217;s review and decision making for the overall compensation strategy, Radford provided the Compensation Committee with a peer group proxy study, general biopharma industry market data, benchmarks and recommendations for equity awards for executives. Radford does not provide services to our management without the Compensation Committee&#8217;s approval, but has been directed by the Compensation Committee to work in cooperation with management as necessary to gather information to carry out its obligation to the Compensation Committee. The Compensation Committee has assessed the independence of Radford pursuant to SEC and Nasdaq rules and concluded that no conflict of interest exists that would prevent Radford from serving as an independent consultant to the Compensation Committee.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Compensation Committee took into consideration the review and recommendations of Radford when making decisions about our executive compensation program, ultimately, the Compensation Committee made its own independent decisions about compensation matters.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Role of the Chief Executive Officer</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee works with our Chief Executive Officer to set the target total direct compensation of each of our named executive officers other than our Chief Executive Officer. As part of this process, our Chief Executive Officer evaluates each named executive officer, determines his recommendations about the target compensation of each named executive officer and delivers his evaluations and compensation recommendations to the Compensation Committee. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taking into account the Chief Executive Officer&#8217;s evaluations and recommendations and other information it deems relevant, such as our achievement of corporate goals, the executive officer&#8217;s achievement of individual goals, responsibilities and experience, as well as the compensation philosophy described above and with reference to the peer group data, the Compensation Committee sets the target total direct compensation of our named executive officers. The Compensation Committee sets the compensation for our Chief Executive Officer and each of our named executive officers.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive Considerations</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Compensation Committee&#8217;s determination of compensation for fiscal year 2020, the Committee reviewed the aggregate level of total compensation of our executives, the combination of elements used to compensate our executives as well as a comparison to the compensation of named executive officers of the companies referred to as our &#8220;peer group&#8221; as a reference point of compensation levels. In 2020, in light of our then-current size and status, there was a modest adjustment to the criteria we used to review and select peers&#58; our market capitalization range was reduced from $140 million - $1.3 billion to $100 million - $900 million&#59; headcount range was reduced from 100 &#8211; 900 employees to 50 &#8211; 600 employees. In addition, we re-evaluated and revised the peer group taking into consideration not only the adjusted criteria but also changes to the stage of development of the companies in the peer group used for 2019 compensation analysis and decisions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, we removed six companies (Acceleron Pharma, Aduro Biotech, Celldex Therapeutics, Idera Pharmaceuticals, NewLink Genetics, and Vital Therapies because they no longer fit the peer group criteria. These companies were replaced by BioCryst Pharmaceuticals, Calithera Biosciences, Cellular Biomedicine Group, Deciphera Pharmaceuticals, Syndax Pharmaceuticals, and Syros Pharmaceuticals. The 22 companies in our peer group were selected based on industry comparability, size and similarity in the stage of product development. We strive to achieve a peer group that results in Inovio being near the median in the group. The criteria for the selection were as follows&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and pharmaceutical companies&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies primarily with product candidates in Phase 2 or Phase 3 clinical trials, with a preference towards immuno-oncology and oncology vaccine development&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market capitalization between $100 million and $900 million&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Between 50-600 employees.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using the above criteria, the following companies were used to comprise the 2020 peer group&#58;</font></div><div style="margin-bottom:11pt;margin-top:11pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Achillion Pharmaceuticals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Prime Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agenus</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geron</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arbulus Biopharma</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jounce Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioCryst Pharmaceuticals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karyopharm Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioTime</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macrogenics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calithera Biosciences</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novavax</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cellular Biomedicine Group</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progenics Pharmaceuticals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cytokinetics</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seres Therapeutics</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deciphera Pharmaceuticals</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Syndax Pharmaceuticals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dynavax Technologies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Syros Pharmaceuticals</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epizyme</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology</font></td></tr></table></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the approval of this peer group in August 2019, in early 2020, due in part to attention to our COVID-19 vaccine candidate INO-4800, we experienced a dramatic increase in market capitalization leading to a market capitalization of approximately $1.4 billion at the time compensation decisions were being made in the first quarter of 2020. The following table summarizes the peer group market capitalization statistics as compared to our market capitalization at the time compensation decisions were being made.</font></div><div style="text-indent:24.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peer Group Statistics</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Capitalization (millions)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Percentile</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$213</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Percentile</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$308</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Percentile</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$474</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,400</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Percentile Rank</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highest</font></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee does not benchmark compensation or make decisions with respect to compensation arrangements and amounts solely based on peer data, but refers to peer data to help ensure that target compensation amounts selected by the Compensation Committee do not materially deviate from market practices and that target amounts provide fair compensation given individual and company performance. In particular, the Compensation Committee requested data from Radford at the 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile, median and 75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of our peer group for base salary, target annual bonus, actual annual bonus, aggregate equity award value, total target compensation and total actual compensation. However, individual compensation decisions may deviate from the peer data, as our Compensation Committee discussed the peer data and made the 2020 compensation decisions in the context of the factors discussed below under the section titled &#8220;Compensation Components.&#34;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Components</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive compensation primarily consists of base salary, cash incentive compensation and long-term equity-based compensation. We place significant emphasis on performance-based incentive compensation that focuses on our executives&#8217; efforts to deliver both short-term and long-term value for our stockholders without encouraging excessive risk taking.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors our Compensation Committee considered for each of our executives in 2020 included&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overall corporate performance during 2020 as measured against predetermined performance goals&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The roles and responsibilities of our executives in executing the corporate goals&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our executives&#8217; performance during 2020 in general and as measured against predetermined performance goals&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The roles and responsibilities of our executives&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The individual experience and skills of our executives&#59;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any contractual commitments we have made to our executives regarding compensation&#59; and</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compensation paid by similar companies to their executives with similar roles and responsibilities.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salaries of executive officers are reviewed and approved annually by our Compensation Committee and adjustments are made based on (i)&#160;salary recommendations from our Chief Executive Officer, (ii)&#160;individual performance of executive officers for the previous fiscal year, (iii)&#160;our financial results for the previous year, and (iv)&#160;our financial condition. Our Chief Executive Officer does not make recommendations regarding his own compensation. In addition, in establishing the total compensation package for our Chief Executive Officer, the Compensation Committee pursues the same objectives and policies that apply for our other executive officers.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salary reflects job responsibilities, value to us and individual performance, taking into consideration the need to attract and retain our executives. We determine salaries for our named executive officers initially by reference to each executive&#8217;s employment agreement, which we describe below. The Compensation Committee determines any increase over these salaries based upon recommendations of our Chief Executive Officer and other factors, except in the case of the Chief Executive Officer&#8217;s own compensation. The Compensation Committee generally reviews base salaries of our executives annually and adjusts salaries from time to time to realign salaries with market levels, individual performance and the performance of the Company.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of individual and corporate accomplishments along with the executive officer&#8217;s level of responsibility, competitive factors and our internal policies regarding salary increases were considered regarding 2020 salary increases. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual base salaries for each of our named executive officers for 2019 and 2020 were as follows&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 Salary ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Salary ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (%)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,976</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,345</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,134</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,591</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:22.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salary increases for our Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer and Chief Operating Officer for 2020 were 3%, 5%, 10% and 10%, respectively. Increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s were given in order for the adjusted base salaries to be at approximately the 50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile within our peer group for those executives. </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based Annual Cash Incentive Compensation</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for an annual cash incentive that reinforces our pay-for-performance approach. This incentive compensation is a short-term incentive program that rewards achievement of annual goals and objectives. At the end of each calendar year, annual incentive awards are awarded at the sole determination of the Compensation Committee (on behalf of the Board) based on the actual and measurable performance of the Company based on a set of predetermined corporate objectives established and communicated to executives at the beginning of the previous year.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Chief Executive Officer provides company goals to the Board for review and the Board reviews and approves the goals and assigns weightings. The weightings for each goal vary year to year depending on the importance of the goal for a particular year. At the end of the year, the Compensation Committee measures actual performance against the predetermined performance goals, using measurable performance parameters, to determine an overall corporate performance score that is then multiplied by each executive&#8217;s target bonus, which is expressed as a percentage of base salary.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each named executive officer&#8217;s target bonus percentage was unchanged from 2019, consistent with our philosophy that a significant portion of each executive&#8217;s total target compensation should be performance-based, and reflected the Compensation Committee&#8217;s review of internal pay equity. The Compensation Committee also considered the recommendation of our Chief Executive Officer that target levels for the other officers not change from 2019 levels and concluded that there were no extraordinary factors creating a need to modify the 2019 target bonus levels.  </font></div><div style="margin-bottom:13pt;margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporate goals for 2020 were similar to those in 2019, focusing on the clinical and preclinical development of our product candidates, as well as other strategic goals such as fundraising and business development. The 2020 corporate performance score was the sum of the achievement levels of the following corporate objectives, as further described below&#58;</font></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Corporate Objectives</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Weighting</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual Achievement</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance preparation of Biologics License Application (BLA) and commercialization&#58; VGX-3100</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance orphan disease program&#58; RRP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance oncology and orphan disease programs</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advance infectious disease programs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other corporate objectives (including financing and business development)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110%</font></td></tr></table></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The target weightings set forth in the table above were comprised of the following components&#58;</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VGX-3100&#58;</font></div><div style="padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">20% based on enrollment levels and numbers of patients dosed in our REVEAL1 and REVEAL2 Phase 3 trials on specified timeframes&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">6% based on presentation of top line efficacy data for our VIN and AIN Phase 2 trials on specified timeframes&#59; and</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">10% in the aggregate for various activities in support of clinical development of this product candidate, including collaborations with third parties and commercial readiness projects. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing Orphan Disease Program&#58;</font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">13% for advancing our RRP development program including IND authorization to proceed and first patient dosed on specified timelines&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing Oncology Programs&#58;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12% for advancement and presentation of data readouts for our Phase 1 trial for INO-5401 + cemiplimab in glioblastoma patients&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2% in the aggregate for advancing the clinical development of product candidates being developed in collaboration with AstraZeneca and the Parker Institute for Cancer Immunology (PICI)&#59; and</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1% in the aggregate for activities associated with the development of our earlier-stage product candidates.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing Infectious Disease Programs&#58;</font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12% for enrollment and other development activities associates with INO-4800 in the United States, China and Korea&#59; and </font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">7% for enrollment and other development activities associates with our DNA vaccine programs for Lassa fever and MERS, including reporting clinical data in peer-reviewed publications.</font></div><div style="margin-top:5pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Corporate Objectives&#58;</font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12% in the aggregate for raising specified amounts of capital during the year&#59;</font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3% in the aggregate for publication of preclinical data in peer-reviewed journals and filing of new patents&#59; and</font></div><div style="margin-top:5pt;padding-left:58.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2% in the aggregate for the development of company-wide strategic operating plans.  </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each corporate objective described above, partial credit could be given by the Compensation Committee based on the actual level of achievement.  In the event that achievement of a predetermined stretch goal within the objectives described above was achieved, the Compensation Committee could give up to 50% extra credit for that objective.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time the Compensation Committee set our goals for 2020, the Compensation Committee believed that each of the corporate objectives were achievable at the target level, but only with significant effort.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our performance against the corporate objectives resulted in a corporate score of 110%, calculated as follows, compared to a 2019 corporate performance score of 103.6%.</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We nearly achieved the REVEAL1 efficacy data readout target and the REVEAL2 dosing target, with delays due to the global pandemic, collectively yielding 16.2% credit of the possible 20%&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We met the targets for our VIN and AIN Phase 2 trials, yielding 6% credit&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We achieved several of the other development goals for VGX-3100, yielding an aggregate of 10% credit&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We achieved our goals with respect to advancement of our RRP program, including the first patient dosed in 2020, yielding 13% credit&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We achieved our targets with respect to the advancement and timing of data presented for our INO-5401 program, yielding 12% credit&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We successfully supported the programs being funded by AstraZeneca and PICI as well as our earlier-state product candidates, yielding a total of 3% credit&#59; </font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We significantly exceeded the goals surrounding INO-4800, yielding 18% credit (which was 150% of the target weighting of 12% credit)&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We partially met the goals associated with the development of our other infectious disease programs, yielding aggregate 5.1% credit (of the possible 7% credit)&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We significantly exceed our financing goal and raised approximately $462.5 million in proceeds from the issuance of common stock under our &#8220;at the market&#8221; equity program and obtained significant external grant funding, yielding aggregate 18% credit </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(which was 150% of the target weighting of 12% credit)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59;</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We significantly exceeded our goals with respect to peer-reviewed publications and patent filings, yielding 4.5% credit (which was 150% of the target weighting of 3% credit)&#59; </font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We achieved our goals for strategic development plans, yielding 2% credit&#59; and</font></div><div style="margin-top:5pt;padding-left:60.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We achieved additional significant accomplishments including establishing multiple agreements to expand large-scale manufacturing capacity, as well as maintaining continuous operations through the global pandemic with high productivity, yielding an additional 2.2% credit.   </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on achievement of the foregoing components, actual bonus payouts to our named executive officers for 2020 performance were at 110% of the targeted amounts. These payouts were not adjusted despite any impacts of COVID-19 on our </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. The actual payouts to each named executive officer for 2020 performance are set forth below and in the Summary Compensation Table under the &#8220;Non-Equity Incentive Plan Compensation&#8221; column.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Salary ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Opportunity (%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Opportunity ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Performance Payout Percentage (%)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Payout ($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,345</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,574</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,032</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,591</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,236</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><font><br></font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Equity-Based Incentive Compensation</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term incentive program provides annual awards, and in rare circumstances, one-time awards, which are performance based. The objective of the program is to align compensation for named executive officers over a multi-year period directly with the interests of our stockholders by motivating and rewarding creation and preservation of long-term stockholder value. We believe that we can maximize our long-term performance best if we tie the value of the long-term benefits our executives receive to our long-term performance.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has structured the 2020 mix of equity vehicles and the relative weight assigned to each to motivate achievement relative to performance metrics for our COVID-19 product candidate as well as stock price growth. More specifically, the forms of equity compensation to our executive officers in 2020 were 50% performance-based restricted stock units (PSUs) and 50% time-based restricted stock units (RSUs). This was a shift from our historical approach of granting a mix of options and RSUs. Prior to the COVID-19 pandemic, we had begun designing a PSU program for the 2020 equity grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, at the time we typically make equity grants (March 2020&#59; at the beginning of the COVID-19 pandemic), our goals significantly shifted to focus on key milestones associated with our COVID-19 vaccine candidate INO-4800. In addition, we were experiencing extraordinary stock price volatility, complicating the equity grant decision-making process. As a result, the Compensation Committee made the decision to grant the time-based RSU award during the normal grant cycle, but revisit the PSU program at a later date when the Committee was better positioned to set performance goals in connection with the development of INO-4800. As a result, the RSU and PSU awards were granted at different points in time during the year and the PSU grant focused predominantly on milestones associated with the Company&#8217;s COVID-19 vaccine candidate INO-4800.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee receives preliminary recommendations for equity-based awards from our Chief Executive Officer. Our Compensation Committee then reviews the market-based recommendations based on our peer group and survey data and recommends equity-based awards for all of our officers, including our Chief Executive Officer and the other named executive officers, to our Board for approval.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each restricted stock unit represents a contingent right to receive one share of common stock. RSUs typically vest over three years in three equal installments beginning on the first anniversary of the grant date. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally grant stock options to our employees, including our named executive officers, in connection with their initial employment with us. The long-term incentives, including stock options, create a strong link between performance and payouts, and a strong alignment between the interests of executive officers and the interests of our stockholders.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term equity-based incentive grant values are targeted to be at the market 50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentiles in aggregate based on the companies in our peer group. This target remained flat year-over-year. The Compensation Committee aims to balance the responsible use of shares with its goals of alignment with stockholders and executive retention, and to do so in 2020 granted time-based RSUs as well as PSUs. The Compensation Committee considers and evaluates the appropriate mix of equity vehicles each year, taking into consideration these various factors.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time-based RSUs granted by the Compensation Committee in March 2020 were as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs <br>(#)(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,499,999</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,160</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,211</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,211</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D. </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,211</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;padding-left:42.75pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.84pt">These RSUs vest over three years in three equal installments beginning on the first anniversary of the grant date. See &#34;Grants of Plan-Based Awards&#34; below, for details on the grant date fair value of these awards.</font></div><div><font><br></font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, the Compensation Committee approved the grant of PSUs to our NEOs under the terms of our 2016 Omnibus Incentive Plan, as amended to date, as set forth in the table below. The PSUs were approved with a specified dollar value and were converted to an equivalent number of shares of common stock based on the closing price of our common stock on the grant date, rounded up to the nearest whole share.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target Value of Award ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Underlying PSU Grant (#)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,216</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,379</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,379</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,000</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,379</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee established the following performance goals and corresponding performance periods over which the performance goals must be attained, the satisfaction of which are conditions to earning the PSUs.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first 20% of the PSUs granted will be earned if our planned Phase 2&#47;3 clinical trial for INO-4800 is fully enrolled. An additional 25% of the PSUs granted will be earned if we receive more than a specified amount of non-dilutive, third-party funding for manufacturing and clinical development of INO-4800. An additional 25% of the PSUs granted will be earned if we complete manufacture of at least 100 million (1 mg equivalent) doses of INO-4800 and arrays and a specified number of delivery devices. The remaining 30% of the PSUs granted will be earned if INO-4800 receives regulatory approval by the U.S. Food and Drug Administration and no more than a specified number of other COVID-19 vaccines have previously received such approval.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the foregoing performance goals has a target achievement date occurring within the next one to three years. However, the Compensation Committee may, in its discretion, give credit for any performance goal achieved after the target deadline.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a goal has been achieved and the respective number of shares underlying a PSU has been earned, 50% of the underlying shares earned will vest on the date of achievement, and the remaining 50% of the underlying shares earned will vest one year thereafter, subject to the executive officer&#8217;s continued employment with us through such date. In the event of a change in control, earned but unvested awards would automatically vest in full to the extent earned. In the event of a change in control, if a performance goal has been substantially completed, the Compensation Committee may, in its discretion, declare the applicable portion of the award to be earned and may accelerate vesting of all or a portion of the awards. In the event of the executive officer&#8217;s termination for cause (as defined in the applicable executive officer&#8217;s employment agreement) or other than for good reason (as defined in the applicable executive officer&#8217;s employment agreement), any unearned awards and any earned but unvested awards would be forfeited. In the event of the executive officer&#8217;s termination other than for cause, the awards would not be forfeited and would remain subject to the aforementioned earning and vesting conditions.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Aspects of Our Compensation Program</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance and Change in Control Benefits</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our named executive officers are eligible for certain severance benefits upon a qualifying termination under the terms of their employment agreements. Our Compensation Committee considers these severance benefits critical to attracting and retaining high-caliber executives. Additionally, our Compensation Committee believes that providing enhanced severance benefits to our Chief Executive Officer and Chief Financial Officer upon a qualifying termination in connection with a change in control minimizes the distractions to these executives in connection with a corporate transaction and reduces the risk that our Chief Executive Officer and Chief Financial Officer depart our company before a transaction is completed. We believe that the severance benefits allow our Chief Executive Officer and Chief Financial Officer to focus on continuing normal business operations and, in the case of change in control severance benefits, the success of a potential business combination, rather than worry about how business decisions that may be in our best interest will impact their own financial security. These existing arrangements help ensure stability, and will help enable our Chief Executive Officer and Chief Financial Officer to maintain a balanced perspective in making overall business decisions during periods of uncertainty. Our Compensation Committee periodically reviews the severance payments and benefits that we provide, including by reference to market data, to ensure they </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remain appropriately structured and at reasonable levels. A more detailed description of the severance and change in control payments and benefits is provided below under &#8220;Potential Payments upon Termination or Change in Control.&#8221;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Benefits</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our named executive officers with the same employee benefits that all of our other employees receive under our broad-based benefit plans. These plans provide for health benefits, life insurance and other welfare benefits.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Perquisites</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide our named executive officers with any perquisites that we do not provide to all of our other employees.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Compensation Policies and Practices</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has considered whether our overall compensation program for employees in 2020 and 2021 creates incentives for employees to take excessive or unreasonable risks that could materially harm our company, and determined that our policies and programs are not reasonably likely to have a material adverse effect on the Company. We believe that several features of our compensation policies for management employees appropriately mitigate such risks, including a mix of long- and short-term compensation incentives that we believe is properly weighted, the uniformity of compensation practices across our company and the use of our 2020 and 2021 business plans, which the Compensation Committee regards as setting an appropriate level of risk taking for us, as a baseline for bonus plan targets for our management. We also believe our internal legal and financial controls appropriately mitigate the probability and potential impact of an individual employee committing us to a harmful long-term business transaction in exchange for short-term compensation benefits.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoupment Policy</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to align further management&#8217;s interests with the interests of our stockholders and to support good corporate governance practices, our Corporate Governance Guidelines provide that, subject to rules of the SEC and the exchange on which our common stock is traded, in the event that we are required to prepare an accounting restatement due to our material noncompliance with any financial reporting requirement under the federal securities laws, we shall recover from any current or former executive officer, as determined in accordance with such rules, who received cash and equity-based compensation (including stock options awarded as compensation) during the three-year period preceding the date on which we are required to prepare an accounting restatement, based on the erroneous data, in excess of what would have been paid to the executive officer under the accounting restatement and any respective profits that officer has realized from the sale of our securities during the 12-month period preceding the date on which we are required to prepare an accounting restatement.</font></div><div style="margin-top:5pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Considerations</font></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting impact of our executive compensation program is one of many factors that the Compensation Committee considers in determining the size and structure of our compensation program.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deductibility of Executive Compensation Under Section&#160;162(m) of the Code</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 162(m) of the Code, compensation paid to any publicly held corporation&#8217;s &#8220;covered employees&#8221; that exceeds $1 million per taxable year for any covered employee is generally non-deductible. Prior to the enactment of the Tax Cuts and Jobs Act, Section 162(m) of the Code provided a performance-based compensation exception, pursuant to which the deduction limit under Section 162(m) of the Code did not apply to any compensation that qualified as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code. Pursuant to the Tax Cuts and Jobs Act, the performance-based compensation exception under Section 162(m) of the Code was repealed with respect to taxable years beginning after December 31, 2017, except that certain transition relief is provided for compensation paid pursuant to a written binding contract which was in effect on November 2, 2017 and which is not modified in any material respect on or after such date. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation paid to each of the Company&#8217;s &#8220;covered employees&#8221; in excess of $1 million per taxable year generally will not be deductible unless it qualifies for the performance-based compensation exception under Section 162(m) of the Code pursuant to the transition relief described above. Because of certain ambiguities and uncertainties as to the application and interpretation of Section 162(m) of the Code, as well as other factors beyond the control of the Compensation Committee, no assurance can be given that any compensation paid by the Company will be eligible for such transition relief and be deductible by the Company in the future. Although the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for the Company&#8217;s named executive officers in a manner consistent with the goals of the Company&#8217;s executive compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not deductible by the Company due to the deduction limit under Section 162(m) of the Code. The Compensation Committee also retains the flexibility to modify compensation that was initially intended to be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exempt from the deduction limit under Section 162(m) of the Code if it determines that such modifications are consistent with the Company&#8217;s business needs.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Ownership Guidelines and Policies</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, our Compensation Committee adopted stock ownership guidelines for our directors and officers. Our Compensation Committee, in consultation with Radford, determined that stock ownership guidelines are common among large public companies and are increasing in prevalence among mid-sized and smaller companies. The Compensation Committee also determined that stock ownership guidelines help align the interests of our executives with those of our stockholders and may act as a risk mitigation device.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock ownership guidelines are based on a multiple of base salary or annual cash retainer, as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Position</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership Guideline</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 times annual base salary</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Executive Officers</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 times annual base salary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Employee Director</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 times annual base cash retainer (not including amounts received for service on Board committees)</font></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of these guidelines, &#8220;ownership&#8221; includes&#58; (1)&#160;shares owned directly by the individual (or jointly with the individual&#8217;s spouse) and by members of the individual&#8217;s immediate family&#59; (2)&#160;shares held in trust for the benefit of the individual and&#47;or his or her immediate family members residing in the same household&#59; (3)&#160;shares subject to outstanding stock options held by the individual (but only to the extent vested and with an exercise price less than the average of the daily closing sales price of our common stock for the last 90 trading days of the immediately preceding calendar year&#59; and (4) 50% of the shares subject to unvested RSUs held by the individual.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and directors have until the later of December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the year in which the officer or director achieves his or her fifth year of service as an officer or director, and December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the fifth year following the year in which the individual becomes subject to the ownership guidelines to comply with the guidelines.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy Regarding Hedging and Pledging of Our Common Stock</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our stock ownership guidelines, our executive officers and directors are also subject to our Amended and Restated Code of Business Conduct and Ethics, which prohibits all employees and directors from purchasing financial instruments designed to hedge or offset any decrease in the market value of the Company&#8217;s common stock or engage in any transaction that would have the effect of reducing or eliminating the economic risk of holding the Company&#8217;s common stock (including, but not limited to, prepaid variable forward contracts, equity swaps, collars, and exchange funds). Our executive officers and directors are also subject to our Amended and Restated Insider Trading Policy, which prohibits all employees and directors from engaging in short-term or speculative transactions in the Company&#8217;s securities, including pledging and purchasing Company securities on margin.</font></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_25"></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the compensation of our named executive officers for 2020, 2019 and 2018.</font></div><div style="margin-bottom:14pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name and Principal Position</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br>($)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards      ($)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Awards<br>($)(3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan ($) (4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other<br>Compensation<br>($)(5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total ($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,645&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,499,999&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,032&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,707,676&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief                      Executive Officer </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837,735&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,222&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726,798&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,545,687&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,922&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,386&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081,043&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,010&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153,905&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,712&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,010&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142,936&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,886&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,783&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,612&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,321&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,010&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331,612&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.                 </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137,365&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Chief Scientific Officer (6)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,903&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,760&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972,531&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.                </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,769&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,946&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137,311&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Chief Operating Officer (7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,120&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,760&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,154&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157,034&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Salary includes contributions made by the employee to our 401(k) plan and payouts of accrued but unused vacation time. </font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Represents the grant date fair values of RSUs and PSUs computed in accordance with FASB ASC Topic 718. See Note&#160;13 &#8220;Stockholders' Equity&#8221;, to our audited consolidated financial statements for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, for the assumptions made in determining stock compensation values. For the PSUs granted in 2020, no amounts are included in this column as the underlying performance conditions were deemed to be not probable of achievement as of the grant date. Assuming the highest level of achievement of the PSUs as of the grant date, the fair values would be $3,500,000 for Dr. Kim and $1,500,000 for each of Mr. Kies, Dr. Humeau and Ms. Shea.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Represents the grant date fair value of stock options computed in accordance with FASB ASC Topic 718. See Note&#160;13 &#8220;Stockholders' Equity&#8221;, to our audited consolidated financial statements for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K, for the assumptions made in determining stock compensation values. During the year ended December 31, 2020, the named executive officers were not granted any stock options.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">The amounts in this column reflect cash incentive bonuses earned during the respective year and paid during the first quarter of the following year. See &#8220;Compensation Discussion and Analysis-Compensation Components- Performance-Based Annual Cash Incentive Compensation&#8221; for additional information regarding bonus payouts earned for 2020.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Represents company 401(k) match amounts for the indicated year. </font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Appointed as Chief Scientific Officer on March 8, 2019, but amounts for 2019 include amounts earned as an employee for the period prior to appointment as an executive officer.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Commenced employment as Chief Operating Officer on March 25, 2019.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants of Plan-Based Awards</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to stock awards and other plan-based awards granted to our named executive officers during 2020.  During 2020 the named executive officers were not granted any stock options. </font></div><div style="margin-bottom:14pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Possible Payouts Under Non-Equity Incentive Plan Awards (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Possible Payouts Under Equity Incentive Plan Awards (2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Stock Awards&#58; Number of Shares of Stock or</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date<br>Fair Value<br>of&#160;Stock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target ($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Threshold (#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Target (#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum (#)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Units (#) (3)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards    ($)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454,574&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545,489&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;11&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,499,999&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;28&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,043&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,236&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,284&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;11&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;28&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;11&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;28&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,875&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;11&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,499,996&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;28&#47;2020</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Non-equity incentive plan awards represent the target and maximum amounts of cash incentive compensation payable under our annual cash incentive plan. The actual amounts earned are disclosed in the &#8220;Non-Equity Incentive Plan Compensation&#8221; column of the Summary Compensation Table. There are no threshold payouts, as partially met goals can receive a proportional score based on the partial achievement. Target payments amounts are paid at 100% of the target incentive and assume goal attainment of 100% of the corporate performance measurement score. Maximum payment amounts reflect 120% of the annual target incentive, which assumes the attainment of the other corporate goals. For additional information regarding the annual cash incentive plan, see &#8220;Compensation Discussion and Analysis&#8221; above.</font></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">PSUs are granted at target at the grant date. Actual shares to vest over a one-year period will be based on achievement of pre-defined goals, described above under &#8220;Compensation Discussion and Analysis&#8212;Compensation Components&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-Term Equity-Based Incentive Compensation.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threshold payout amounts assume only the attainment of the goal with the lowest weighting (20%). Target and maximum payout amounts assume attainment of 100% of the target goals in the specified timeframes. Once a goal has been achieved and the respective number of shares underlying a PSU has been earned, 50% of the underlying shares earned will vest on the date of achievement, and the remaining 50% of the underlying shares earned will vest one year thereafter, subject to the executive officer&#8217;s continued employment with us through such date.</font></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;       These RSUs vest over three years in three equal installments beginning on the first anniversary of the grant date.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font><br></font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth certain information with respect to outstanding equity awards held by the named executive officers at December&#160;31, 2020.</font></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OPTION AWARDS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STOCK AWARDS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;   Securities<br>Underlying<br>Unexercised<br>Options (#)<br>Exercisable</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;  Securities<br>Underlying<br>Unexercised<br>Options (#)<br>Unexercisable (1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Exercise<br>Price($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br>Expiration<br>Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares or Units of Stock That Have Not Vested (#) </font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Value of Shares or Units of Stock That Have Not Vested ($) (2)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards&#58; Number of Unearned Shares or Units of Stock That Have Not Vested (#)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Incentive Plan Awards&#58;  Unearned Shares or Units of Stock That Have Not Vested ($)    (2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.56&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.92&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;26&#47;2024</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.80&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#47;22&#47;2024</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2025</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#47;8&#47;2025</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.02&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;9&#47;2026</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,150&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;10&#47;2027</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,688&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,562&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.29&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2028</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,885&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;8&#47;2029</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,127,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700,716&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#47;28&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568,412&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780,388&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,612&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">665,660&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,891,091&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,216&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568,412&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.92&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;26&#47;2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.80&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#47;22&#47;2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;9&#47;2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.68&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;10&#47;2027</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,625&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2028</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,566&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,959&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,250&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;8&#47;2029</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,933&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379,957&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586,017&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#47;28&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512,625&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,875&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,710&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,209,933&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.00&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#47;6&#47;2024</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2025</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.02&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;9&#47;2026</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;10&#47;2027</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,875&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.29&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;5&#47;2028</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,566&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,959&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;8&#47;2029</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#47;28&#47;2030</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,225&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,225&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246,577&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;25&#47;2029</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,333&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294,997&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#47;11&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586,017&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#47;28&#47;2030</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,544&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881,014&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,379&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,754&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These stock option awards vest 25% immediately on the date of grant and 25% on each anniversary thereafter.  The option expiration date as reflected in the table is the tenth anniversary of the grant date.</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:42.34pt">The market value of RSUs and PSUs that have not vested is based on $8.85 per share, the closing price of our common stock on the Nasdaq Global Select Market on December 31, 2020.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These RSUs vested in full on March 5, 2021.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These RSUs vested as to one-half of the shares on March 8, 2021 and the remainder will vest on March 8, 2022.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These RSUs vested as to one-half of the shares on March 25, 2021 and the remainder will vest on March 25, 2022.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These RSUs vested as to one-third of the shares on March 11, 2021, and the remainder will vest in two equal installments on March 11, 2022 and March 11, 2023.</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">These PSUs will vest based on achievement of pre-defined goals, described above under &#8220;Compensation Discussion and Analysis&#8212;Compensation Components&#8212; Long-Term Equity-Based Incentive Compensation.&#8221;  Once a goal has been achieved and the respective number of shares underlying a PSU has been earned, 50% of the underlying shares earned will vest on the date of achievement, and the remaining 50% of the underlying shares earned will vest one year thereafter, subject to the executive officer&#8217;s continued employment with us through such date.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options Exercised and Stock Vested During Fiscal Year 2020 </font></div><div><font><br></font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on stock option exercises and vesting of RSUs in fiscal 2020 for our named executive officers.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OPTION AWARDS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STOCK AWARDS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br>Acquired Upon Exercise(#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value Realized Upon Exercise ($)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Acquired On Vesting (#)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value Realized on Vesting ($)(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,677,003&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter D. Kies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,613&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,467&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,576&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><font><br></font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The value realized upon exercise of stock options reflects the price at which shares acquired upon exercise of the stock options were sold on the date of exercise or otherwise valued for income tax purposes, based on the closing price of our common stock on the date of exercise, net of the exercise price for acquiring the shares. </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Computed by multiplying the closing market price of our common stock on the vesting date by the number of  RSUs subject to such award vesting on the applicable vesting date.</font></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer Pay Ratio</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to disclose the ratio of our principal executive officer&#8217;s annual total compensation to the annual total compensation of our median employee. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal 2020, our principal executive officer was our President and Chief Executive Officer, J. Joseph Kim, Ph.D. For 2020, the annual total compensation for Dr. Kim was $4,707,676. The annual total compensation for our median employee (identified as disclosed below) was $185,948 resulting in a pay ratio of approximately 25&#58;1. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Item 402(u) of Regulation S-K, we identified a new median employee as of November 29, 2020 (the median employee determination date), by (i) aggregating for each applicable employee (A) base salary as of November 29, 2020 (or hourly rate multiplied by estimated work schedule, for hourly employees), (B) the target bonus for 2020 and, (C) the estimated grant date fair value of any equity awards granted during 2020, and (ii) ranking this compensation measure for our employees from lowest to highest. This calculation was performed for all employees of the Company, excluding Dr. Kim. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median-compensated employee and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculating the pay ratio based on that employee&#8217;s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreement with J. Joseph Kim, Ph.D. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an executive employment agreement entered into in 2008 and amended in 2012, J. Joseph Kim, Ph.D. serves as our Chief Executive Officer. The agreement provides that Dr.&#160;Kim is entitled to receive an annual salary, subject to upward adjustment. Dr.&#160;Kim&#8217;s base salary as of March 1, 2021 is $720,326. He is also eligible to receive an incentive cash bonus, based upon the criteria as may be determined by our Board, with a target of 65% of his base salary. In addition to the salary and cash bonus, he is also entitled to participate in our employee benefit plans or programs, and shall be entitled to such other fringe benefits, as are from time to time adopted by our Board.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr. Kim employment is terminated by reason of death or total disability, we will pay Dr. Kim or his estate or representative, as applicable, any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under any of our plans and programs in which Dr. Kim is then participating, and, in the case of total disability, a continuation of medical benefits for up to 60 days and COBRA premiums for 24 months thereafter or, if earlier, the termination of such COBRA coverage, with such premiums to provide for coverage at the same level and subject to the same terms and conditions as in effect at the time of termination. In the case of total disability, Dr. Kim will also receive a lump-sum payment equal to 24 months of his aggregate base salary then in effect.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Dr. Kim&#8217;s employment for cause, as defined in the agreement, we will pay him any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses and all other accrued but unpaid rights as determined under our plans and programs in which he is then participating. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Dr.&#160;Kim&#8217;s employment agreement, if we terminate his employment other than on account of death, total disability or cause, as defined in the employment agreement, or Dr. Kim terminates his employment for good reason, as defined in the agreement, Dr.&#160;Kim is entitled to receive any unpaid portion of his base salary computed on a pro-rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under our plans and programs in which Dr.&#160;Kim is then participating, severance compensation in the amount of 24 months of his then current base salary and 24 months aggregate of the pro rata bonus amount following the effective date of such termination. The pro rata bonus amount shall mean one-twelfth of the greater of (A)&#160;the most recent annual cash bonus paid prior to his termination, or (B)&#160;the average of the three most recent annual cash bonuses paid prior to his termination. We will also continue to pay his COBRA premiums for 24&#160;months thereafter.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr.&#160;Kim is terminated as a result of change in control, Dr.&#160;Kim is entitled to receive payments due to him under the conditions of termination without cause as outlined above and a lump-sum cash severance payment equal to his then-current monthly base salary and the pro rata bonus amount multiplied by 24 but discounted to present value based on applicable federal rate under the Code.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any amount paid, distributed or treated as paid or distributed by the Company to or for Dr. Kim&#8217;s benefit&#160;(a &#8220;Payment&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code in connection with a change in control, or if any interest or penalties are incurred by Dr. Kim with respect to such excise tax (such excise tax, together with any such interest and penalties, the &#8220;Excise Tax&#8221;), Dr. Kim will be entitled to receive an additional payment (a &#8220;Gross-Up Payment&#8221;) in an amount such that after payment by Dr. Kim of all federal, state and local taxes (including any interest or penalties with respect to such taxes), including, any income taxes (and any interest and penalties with respect to such taxes) and Excise Tax imposed upon the Gross-Up Payment, Dr. Kim retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon all the Payments.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreement with Peter&#160;D. Kies </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an employment agreement with Mr. Kies pursuant to which he serves as Chief Financial Officer. The employment agreement provides an annual base salary, subject to upward adjustment yearly by our Board or its Compensation Committee. Mr.&#160;Kies&#8217; base salary as of March 1, 2021 is $464,108. Under the employment agreement, Mr. Kies is eligible to receive an incentive cash bonus up to the amount, based upon the criteria and payable at such times as determined by our Board or its Compensation Committee. Mr. Kies&#8217; current target bonus is 40% of his base salary. Mr. Kies is also entitled to participate in such employee benefit plans and programs and is entitled to such other fringe benefits, as are from time to time adopted by our Board or its Compensation Committee and made available by us generally to employees of similar position, and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall be eligible for such awards and benefits, if any, pursuant to our plans and programs as determined by our Board or its Compensation Committee.  </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Kies&#8217; employment is terminated by reason of death or total disability, we will pay Mr. Kies or his estate or representative, as applicable, any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under any of our plans and programs in which Mr. Kies is then participating, and, in the case of total disability, a continuation of medical benefits for up to 60 days and COBRA premiums for six months thereafter. In the case of total disability, Mr. Kies will also receive a lump-sum payment equal to six months of his aggregate base salary then in effect.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Mr. Kies&#8217; employment for cause, as defined in the agreement, we will pay him any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses and all other accrued but unpaid rights as determined under our plans and programs in which he is then participating.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Mr. Kies&#8217; employment other than on account of death, total disability or cause, or Mr. Kies terminates his employment for good reason, as defined in the agreement, on 30 days&#8217; prior written notice, we will pay him any unpaid portion of his base salary computed on a pro-rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under our plans and programs in which Mr. Kies is then participating, a severance payment in the amount of 12 months of base salary and COBRA payments for 12&#160;months following the effective date of termination. The employment agreement requires that Mr. Kies enter into an agreement containing certain non-competition and non-disclosure covenants.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Kies is terminated as a result of change in control, Mr. Kies is entitled to receive payments due to him under the conditions of termination without cause as outlined above and a lump-sum cash severance payment equal to his then-current monthly base salary and the pro rata bonus amount multiplied by 12 but discounted to present value based on applicable federal rate under the Code. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreement with Laurent M. Humeau, Ph.D. </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement with Dr.&#160;Humeau pursuant to which he has served as Chief Scientific Officer and Executive Vice President since March 2019. The employment agreement provides an annual base salary, subject to upward adjustment yearly by our Board or its Compensation Committee. Dr.&#160;Humeau's base salary as of March 1, 2021 is $453,200. Under the employment agreement, Dr.&#160;Humeau is eligible to receive an incentive cash bonus up to the amount, based upon the criteria and payable at such times as determined by our Board or its Compensation Committee. Dr.&#160;Humeau's current target bonus is 40% of his base salary. Dr.&#160;Humeau is also entitled to participate in such employee benefit plans and programs and is entitled to such other fringe benefits, as are from time to time adopted by our Board or its Compensation Committee and made available by us generally to employees of similar position, and shall be eligible for such awards and benefits, if any, pursuant to our plans and programs as determined by our Board or its Compensation Committee.  </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr.&#160;Humeau's employment is terminated by reason of death or total disability, we will pay Dr.&#160;Humeau or his estate or representative, as applicable, any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under any of our plans and programs in which Dr.&#160;Humeau is then participating, and, in the case of total disability, a continuation of medical benefits for up to 60 days and COBRA premiums for twelve months thereafter. In the case of total disability, Dr.&#160;Humeau will also receive a lump-sum payment equal to twelve months of his aggregate base salary then in effect.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Dr.&#160;Humeau's employment for cause, as defined in the agreement, we will pay him any unpaid portion of his base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses and all other accrued but unpaid rights as determined under our plans and programs in which he is then participating.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Dr.&#160;Humeau's employment other than on account of death, total disability or cause, or Dr.&#160;Humeau terminates his employment for good reason, as defined in the agreement, on 30 days&#8217; prior written notice, we will pay him any unpaid portion of his base salary computed on a pro-rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under our plans and programs in which Dr.&#160;Humeau is then participating, a severance payment in the amount of 12 months of base salary and COBRA payments for 12&#160;months following the effective date of termination. The employment agreement requires that Dr.&#160;Humeau enter into an agreement containing certain non-competition and non-disclosure covenants.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreement with Jacqueline E. Shea, Ph.D.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement with Dr.&#160;Shea pursuant to which she has served as Chief Operating Officer and Executive Vice President since March 2019. The employment agreement provides an annual base salary, subject to upward adjustment yearly by our Board or its Compensation Committee. Dr.&#160;Shea's base salary as of March 1, 2021 is $453,200. Under the employment agreement, Dr.&#160;Shea is eligible to receive an incentive cash bonus up to the amount, based upon the criteria and payable at such times as determined by our Board or its Compensation Committee. Dr.&#160;Shea's current target bonus is 40% of her base salary. Dr.&#160;Shea is also entitled to participate in such employee benefit plans and programs and is entitled to such other fringe benefits, as are from time to time adopted by our Board or its Compensation Committee and made available by us generally to employees of similar position, and shall be eligible for such awards and benefits, if any, pursuant to our plans and programs as determined by our Board or its Compensation Committee.  </font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr.&#160;Shea's employment is terminated by reason of death or total disability, we will pay Dr.&#160;Shea or her estate or representative, as applicable, any unpaid portion of her base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under any of our plans and programs in which Dr.&#160;Shea is then participating, and, in the case of total disability, a continuation of medical benefits for up to 60 days and COBRA premiums for twelve months thereafter. In the case of total disability, Dr.&#160;Shea will also receive a lump-sum payment equal to twelve months of her aggregate base salary then in effect.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Dr.&#160;Shea's employment for cause, as defined in the agreement, we will pay her any unpaid portion of her base salary computed on a pro rata basis through the date of termination, any unreimbursed expenses and all other accrued but unpaid rights as determined under our plans and programs in which she is then participating.</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we terminate Dr.&#160;Shea's employment other than on account of death, total disability or cause, or Dr.&#160;Shea terminates her employment for good reason, as defined in the agreement, on 30 days&#8217; prior written notice, we will pay her any unpaid portion of her base salary computed on a pro-rata basis through the date of termination, any unreimbursed expenses, all other accrued but unpaid rights as determined under our plans and programs in which Dr.&#160;Shea is then participating, a severance payment in the amount of 12 months of base salary and COBRA payments for 12&#160;months following the effective date of termination. The employment agreement requires that Dr.&#160;Shea enter into an agreement containing certain non-competition and non-disclosure covenants.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Potential Payments upon Termination or Change in Control </font></div><div style="margin-bottom:13pt;margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Had termination without cause, resignation for good reason or termination due to a change in control or other event occurred as of December&#160;31, 2020, our named executive officers would have received the following benefits and payments&#58; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:18pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Involuntary Termination</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefits and Payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Voluntary Termination not for Good Reason ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not For Cause ($) (1)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For Cause ($)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in Control ($)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Death or Total Disability ($)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">J. Joseph Kim, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance pursuant to employment agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,651&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881,366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,651&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-equity incentive plan award (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,064&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,064&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health coverage benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and accelerated equity awards</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891,091&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,891,091&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,161&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,032&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,835,876&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004,038&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Peter D. Kies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance pursuant to employment agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-equity incentive plan award (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health coverage benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,839&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and accelerated equity awards</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209,934&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209,934&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,980&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,260&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566,348&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,153&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Laurent M. Humeau, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance pursuant to employment agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-equity incentive plan award (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health coverage benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and accelerated equity awards</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182,206&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,860,684&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,478&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jacqueline E. Shea, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance pursuant to employment agreement</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-equity incentive plan award (3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health coverage benefits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and accelerated equity awards</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881,014&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,492&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,600&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,478&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Also represents amount payable in the event of voluntary termination for good reason. </font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Represents amounts payable only in the case of total disability&#59; these amounts would not be payable in the event of death. </font></div><div style="margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Assumes named executive officer would have been entitled to receive amount described in the Summary Compensation   Table under the &#8220;Non-Equity Incentive Plan Compensation&#8221; column, or in the case of Dr. Kim, two times that amount in the event of termination not for cause or termination due to a change in control.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our equity compensation plan information as of December&#160;31, 2020. All of our equity compensation plans have been approved by our security holders. Our 2007 Omnibus Incentive Plan was terminated on March 31, 2017 and the following table sets forth awards that remain outstanding under this plan.</font></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:52.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Plan</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>securities to be issued upon exercise of outstanding<br>options and rights (a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>exercise<br>price of outstanding options and rights (b) (1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities<br>remaining available for future issuance<br>under equity compensation<br>plans (excluding securities reflected in column (a))         (c) (2)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Omnibus Incentive Plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,300,161&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,739,577&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2007 Omnibus Incentive Plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,164,515&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,464,676&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,739,577&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The calculation of the weighted-average exercise price of the outstanding options and rights includes 2,558,052 shares included in column (a) that are issuable upon the vesting of RSUs issued under the 2016 Omnibus Incentive Plan, as amended, which have no exercise price. Excluding the RSUs, the weighted-average exercise price of the outstanding options would be $6.78.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;As of January&#160;1, 2021, the number of securities available for future issuance under the 2016 Omnibus Incentive Plan, as amended, automatically increased by 2,000,000 pursuant to the &#8220;evergreen&#8221; provision of such plan.</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Relationships and Related Party Transactions</font></div><div style="margin-top:5pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January&#160;1, 2020, there has not been, nor is there currently proposed, any transaction or series of similar transactions to which we were or are a party in which the amount involved exceeds $120,000 and in which any director, executive officer or beneficial holder of more than 5% of any class of our voting securities or members of such person&#8217;s immediate family had or will have a direct or indirect material interest. Under the charter of our Audit Committee, all related party transactions required to be disclosed under SEC Regulation S-K, Item 404, must be reviewed and approved by our Audit Committee after discussion with management of the business rationale for the transactions and whether appropriate disclosures have been made.  </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font><br></font></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_31"></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RATIFICATION OF APPOINTMENT OF INDEPENDENT</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has appointed Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2021 and has further directed that the appointment of the independent registered public accounting firm be submitted for ratification by our stockholders at the Annual Meeting. Representatives of Ernst&#160;&#38; Young&#160;LLP are expected to be present at the Annual Meeting, will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholder ratification of the appointment of Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm is not required by our bylaws or otherwise. However, our Board is submitting the appointment of Ernst&#160;&#38; Young&#160;LLP to our stockholders for ratification as a matter of good corporate practice. If our stockholders fail to ratify the appointment, the Audit Committee will reconsider whether or not to retain that firm. Even if the appointment is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of us and our stockholders.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of the holders of a majority of the shares present or represented by proxy and voting at the Annual Meeting is required to ratify the appointment of Ernst&#160;&#38; Young&#160;LLP.  Abstentions will be counted the same as if voted against the proposal.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the aggregate fees billed to us for the fiscal years ended December&#160;31, 2020 and 2019 by Ernst&#160;&#38; Young&#160;LLP&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.926%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Audit Fees</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax Fees</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fees</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,200&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,864&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664,064&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242,325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,444&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,769&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Audit fees consist of fees billed for professional services rendered in connection with the audit of our consolidated annual financial statements and internal control over financial reporting, review of the interim consolidated financial statements included in quarterly reports, as well as fees incurred for audit services that are normally provided by Ernst&#160;&#38; Young LLP in connection with other regulatory filings or engagements.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tax fees include fees for services performed by the professional staff in the tax department of Ernst&#160;&#38; Young&#160;LLP except for those tax services that could be classified as audit services. These include tax compliance and various tax consultation fees.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee&#8217;s policy is to pre-approve all audit and permissible non-audit services provided by our independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. The Audit Committee considers whether the provision of each non-audit service is compatible with maintaining the independence of our auditors. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. The independent registered public accounting firm and management are required to periodically report to our Audit Committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval. Our Audit Committee approved all &#34;Audit Fees&#34; and &#8220;Tax Fees&#8221; listed in the table above pursuant to its pre-approval policies and procedures.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Board of Directors unanimously recommends that you vote &#8220;FOR&#8221; the ratification of the appointment of Ernst&#160;&#38; Young&#160;LLP as our independent registered public accounting firm for our fiscal year ending December&#160;31, 2021.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL NO. 3 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-BINDING, ADVISORY VOTE ON EXECUTIVE COMPENSATION</font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our 2017 Annual Meeting of Stockholders, our stockholders determined by a non-binding vote, the frequency with which the compensation of our named executive officers, commonly referred to as a &#8220;say-on-pay&#8221; vote, will be submitted to our stockholders for approval. Even though the alternative for &#8220;three years&#8221; received the most votes at that meeting, the Board has determined that we will submit the compensation of our named executive officers every year to our stockholders for approval, on a non-binding advisory basis. In accordance with the Board&#8217;s intention, we are providing our stockholders with the opportunity to vote, on a non-binding advisory basis, on the compensation of our named executive officers as disclosed in this Proxy Statement. At the 2021 Annual Meeting, our stockholders will vote whether to approve the following non-binding, advisory resolution on the approval of the compensation of the named executive officers&#58;</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;RESOLVED, that the stockholders of the Company approve the compensation of the Company&#8217;s named executive officers, as disclosed in the Company&#8217;s proxy statement with respect to its 2021 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the compensation disclosure and analysis, the compensation tables and the narrative disclosures that accompany those tables in the Company&#8217;s proxy statement for its 2021 annual meeting of stockholders.&#8221;</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. The compensation of our named executive officers that is the subject of the foregoing resolution is the compensation disclosed in the sections titled &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Grants of Plan-Based Awards,&#8221; &#8220;Options Exercised,&#8221; and &#8220;Outstanding Equity Awards at Fiscal Year End,&#8221; and the accompanying narrative disclosures. You are encouraged to carefully review these sections.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The section of this Proxy Statement titled &#8220;Compensation Discussion and Analysis&#8221; includes a detailed discussion of each of the following as it relates to our named executive officers&#58;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; the objectives of our compensation programs&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; what our compensation programs are designed to reward&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; each element of compensation&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; why we choose to pay each element of compensation&#59;</font></div><div style="margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; how we determine the amount, and, where applicable, the formula, for each element to pay&#59; and</font></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; how each compensation element and our decisions regarding that element fit into our overall compensation objectives.</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board unanimously recommends that you approve the foregoing resolution for the same reasons that we decided to provide this compensation to our named executive officers as articulated in the &#8220;Compensation Discussion and Analysis&#8221; section of this proxy statement.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vote Required&#59; Effect of Vote</font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of the resolution in this Proposal&#160;3 requires the affirmative vote of the holders of a majority of the shares present or represented by proxy and entitled to vote at the Annual Meeting. Abstentions could prevent the approval of Proposal 3 because they do not count as affirmative votes.  Broker non-votes will not impact the approval of Proposal 3 because they do not represent shares eligible to be voted on the proposal. </font></div><div style="margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resolution that is the subject of this Proposal&#160;3 is a non-binding, advisory resolution. Accordingly, the resolution will not have any binding legal effect regardless of whether it is approved or not and will not be construed as overruling a decision by us or our Board or to create or imply any change to the fiduciary duties of our Board or any additional fiduciary duties for us or our Board. Furthermore, because this non-binding, advisory resolution primarily relates to compensation of our named executive officers that has already been paid or contractually committed, there is generally no opportunity for us to revisit those decisions. However, our Compensation Committee does intend to take the results of the vote on this Proposal&#160;3 into account in its future decisions regarding the compensation of our named executive officers.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Board of Directors unanimously recommends that you vote &#8220;FOR&#8221; the approval of this resolution under Proposal 3.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCKHOLDER PROPOSALS TO BE PRESENTED AT NEXT ANNUAL MEETING</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; proposals, including proposals under Rule 14a-8 under the Exchange Act, intended to be presented at the next Annual Meeting of Stockholders to be held in 2022 must be received at our principal executive offices no later than December 1, 2021, in order to be considered for inclusion in the proxy statement and form of proxy relating to that meeting. Proposals must comply with the proxy rules relating to stockholder proposals to be included in our proxy materials. Pursuant to our bylaws, stockholders who wish to submit a proposal for consideration at our 2022 Annual Meeting of Stockholders, including a nomination for director, must deliver a copy of their proposal no earlier than October 2, 2021 and no later than December 1, 2021, unless the date of the 2022 Annual Meeting of Stockholders has been advanced more than 30 days prior to, or delayed by more than 30 days after, the anniversary of the 2021 Annual Meeting of Stockholders, in which case the proposal must be received by us no later than the later of the 90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day prior to the 2022 Annual Meeting of Stockholders or the close of business on the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business day following the date on which the 2022 Annual Meeting of Stockholders is publicly announced. If the stockholder is not seeking inclusion of the proposal in our proxy statement, to be timely the notice must be delivered at least 90 days prior to the date of the 2022 Annual Meeting of Stockholders. </font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A director nomination proposal must include the information set forth in our bylaws and as described under &#8220;Director Nominations&#8221; above. In the case of other stockholder proposals other than with respect to stockholder proposals relating to director nomination(s), a stockholder&#8217;s notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting (i)&#160;a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting and (ii)&#160;as to the stockholder giving the notice, the same information regarding the proposing stockholder and any Stockholder Associated Persons as set forth under our bylaws and as described under &#8220;Director Nominations&#8221; above.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proposals should be delivered to Inovio Pharmaceuticals, Inc., 660 W. Germantown Pike, Suite&#160;110, Plymouth Meeting, Pennsylvania 19462, Attn&#58; Corporate Secretary. To avoid controversy and establish timely receipt, it is suggested that stockholders send their proposals by certified mail, return receipt requested. Otherwise, we may exercise discretionary voting with respect to such stockholder&#8217;s proposal pursuant to authority conferred on us by proxies to be solicited by our Board and delivered to us in connection with the meeting. You are also advised to review our bylaws, which may be requested in writing from our Secretary at the address above and which contain additional requirements about advance notice of stockholder proposals.</font></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_43"></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are mailing our Annual Report for the fiscal year ended December&#160;31, 2020 to stockholders of record as of March&#160;16, 2021. Our Annual Report does not constitute, and should not be considered, a part of this Proxy Statement.</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of our Annual Report will be furnished without charge upon receipt of a written request of any person who was a beneficial owner of our common stock on March&#160;16, 2021. Requests should be directed to Inovio Pharmaceuticals, Inc., 660 W. Germantown Pike, Suite&#160;110, Plymouth Meeting, Pennsylvania 19462&#59; Attention&#58; Investor Relations.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSACTION OF OTHER BUSINESS</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the date of this Proxy Statement, the only business which our Board intends to present or knows that others will present at the meeting is as set forth above. If any other matter or matters are properly brought before the meeting, or any adjournment thereof, it is the intention of the persons named in the accompanying form of proxy to vote the proxy on such matters in accordance with their best judgment. Your cooperation in giving this matter your immediate attention and returning your proxies will be appreciated.</font></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:360pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:28.654%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By Order of the Board of Directors</font></div></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"><div><img alt="g696057g43r44a051a.jpg" src="g696057g43r44a051a.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:114px"></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Joseph Kim, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-top:6pt;text-indent:317.25pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; March&#160;25, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plymouth Meeting, Pennsylvania</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><div id="ie49dd27b85de418ab4eeaa7086da42bc_49"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.638%"></td><td style="width:0.1%"></td></tr><tr style="height:53pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">660 W. Germantown Pike</font></div><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Suite 110</font></div><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Plymouth Meeting, PA 19462</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY INTERNET - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">www.proxyvote.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11&#58;59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr style="height:60pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY PHONE - 1-800-690-6903</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Use any touch-tone telephone to transmit your voting instructions up until 11&#58;59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VOTE BY MAIL</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c&#47;o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</font></div></td></tr></table></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS&#58;</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">M35098-Z55250&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;KEEP THIS PORTION FOR YOUR RECORDS</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160; &#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160; &#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160; &#8212;&#160;&#8212;&#160;&#160;&#8212;</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DETACH AND RETURN THIS PORTION ONLY</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;To elect the following directors to serve for a term ending upon the 2022 Annual Meeting of&#160;Stockholders and until their successors are elected and qualified.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For<br>All</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Withhold<br>All</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For&#160;All<br>Except</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">To withhold authority to vote for any individual nominee(s), mark &#8220;For All Except&#8221; and write the number(s) of the nominee(s) on the line below.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="18" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">NOMINEES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">01)&#160;&#160;J. Joseph Kim, Ph.D.<br>02)  Simon X. Benito<br>03)  Ann C. Miller, M.D.                                                                                                       04) Jay P. Shepard</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">05)&#160;&#160;David B. Weiner, Ph.D.<br>06)  Wendy L. Yarno                                                                                                            07)  Lota S. Zoth  <br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="51" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Against</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Abstain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="57" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">To ratify the appointment of Ernst &#38; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting.<br>&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="54" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The undersigned also acknowledges receipt of the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement.<br>&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Please date and sign exactly as your name(s) is (are) shown on the share certificate(s) to which the Proxy applies. When shares are held as joint-tenants, both should sign. When signing as an executor, administrator, trustee, guardian, attorney-in-fact or other fiduciary, please give full title as such. When signing as a corporation, please sign in full corporate name by President or other authorized officer. When signing as a partnership, please sign in partnership name by an authorized person.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature&#160;(PLEASE&#160;SIGN&#160;WITHIN&#160;BOX)&#160;</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date<br>&#160;</font></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signature&#160;(Joint&#160;Owners)</font></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Date</font></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-right:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2021 ANNUAL</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEETING OF STOCKHOLDERS TO BE HELD ON MAY 13, 2021&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Copies of the proxy statement and our 2020 Annual Report to stockholders are also available online at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.inovio.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160; &#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160; </font></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M35099-Z55250&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INOVIO PHARMACEUTICALS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROXY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL MEETING OF STOCKHOLDERS OF INOVIO PHARMACEUTICALS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-right:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned hereby appoints Dr.&#160;J. Joseph Kim, President and Chief Executive Officer and a director of Inovio Pharmaceuticals, Inc., and Simon X. Benito, Chairman of the Board, and each of them, as proxies, each with full power of substitution, and hereby authorizes each of them to represent and to vote, as designated on the reverse side, all the shares of common stock of Inovio Pharmaceuticals, Inc. (including shares of Series C Cumulative Convertible Preferred Stock that are convertible into shares of common stock) held of record by the undersigned as of March 16, 2021 at the Annual Meeting of Stockholders to be held on May 13, 2021, or any adjournment thereof.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER AS DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF THE DIRECTOR NOMINEES LISTED IN PROPOSAL NO. 1 AND FOR PROPOSAL NOS. 2 AND 3. THE UNDERSIGNED STOCKHOLDER MAY REVOKE THIS PROXY AT ANY TIME BEFORE IT IS VOTED BY DELIVERING TO THE CORPORATE SECRETARY OF INOVIO EITHER A WRITTEN REVOCATION OF THE PROXY OR A DULY EXECUTED PROXY BEARING A LATER DATE, OR BY ATTENDING THE ANNUAL MEETING AND VOTING AS INSTRUCTED. THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ELECTION OF THE DIRECTORS LISTED IN PROPOSAL NO. 1 AND &#8220;FOR&#8221; PROPOSAL NOS. 2 AND 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> IF YOU ARE VOTING BY MAIL, PLEASE MARK, SIGN, DATE, AND RETURN THIS CARD PROMPTLY USING THE ENCLOSED RETURN ENVELOPE. IF YOU RECEIVE MORE THAN ONE PROXY CARD, PLEASE SIGN AND RETURN ALL CARDS IN THE ENCLOSED ENVELOPE.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(CONTINUED AND TO BE SIGNED ON REVERSE SIDE)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="border-bottom:2pt solid #000000;border-right:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g696057g43r44a051a.jpg
<TEXT>
begin 644 g696057g43r44a051a.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0M*4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              90   -@    & &< -  S
M '( -  T     0                         !              #8
M90                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     "*T    !    <    #0
M  %0  !$0   ")$ &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  T ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M(  V "X ,     $ .$))300&       '  @  0 ! 0#_[@ .061O8F4 9$
M   !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P/_P  1" !E -@# 1$  A$! Q$!_]T !  ;_\0 :P !  (#  ,!
M      D*!@<(! 4+ @$!                     !    8# 0 !! (" 04
M     @,$!08'  $("1$2$Q0*(146%R,Q(E(S)!$!
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MTC22%O4-_P#9W<<(DW2@\"]"<C4)%28M4A.1JE1(:&_5456A%89Z;<[3JZ+
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MA0&UK3RZ?RMB7I'MP.?/SV]*K<-EI4H!D!5&A<A  !8 EEA"   A    Z"
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M$QQR-,[9'X^R-B<"5M9V1F1$-S4UMZ4K02TR)O0)BR2BPZT$!8-:U_&L#W&
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MP7D)F...C@44@:9(H,&D/^DQ4L"^UTC>L/Y?Y\NWHZP JS(51=5SRV).F;]
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MO;FA3(FQ4K///)(^Z9@;5F_/_OOYO3&G.^V[I"Z/5UYF)Z]#W-P6Q*%K56S
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MZ]9QG&-,%J^&1R P]L,4BT-2:@C45;6IF2&J1AULP19(1#WKY%O>\#8F P&
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M#+V04(O1*X5AQNRW@Z3Q5:TA+%&4CQ%V@"6,#2A>5"AM 8(P/HYX# 8# 8#
18# 8# 8# 8# 8# 8# 8'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
MB5!.1PT*&@H    -24A$4@   NP   '>" 8   # >E['   @ $E$051X >R]
M*Y0E-[)_7?#"2__P@Q<.-1QH:#ATH.% TX:&!4T-&Q9LV-2P84-30\/ZU@YI
MIWZIRE-='K_Z$6>M+"FE4"@4^=#..#I9=X_]:0^T!]H#[8'V0'N@/= >: ^T
M!SY:#]Q]M):U8>V!]D![H#W0'F@/M ?: ^V!]L!C WN?!.V!]D![H#W0'F@/
MM ?: ^V!C]@##>P?\<%IT]H#[8'V0'N@/= >: ^T!]H##>Q]#K0'V@/M@?9
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MR7&H<;L\Z85K[]77:7N@/= >^-@\T,#^L1V1MJ<]T![XKSP M -L@+;15?*
M'>!<F_E8!K*W [:)?*,#L#W:S[;HM)[^]H]@JAWUAAG[G1%\8)+ZJ_:ISX@Q
ML@*H47GL$E"S3>;K 6*^GYQVVH(^H%E=Z,D'#W6P#I^'BZL'#V5,A6;LHI]J
MMZU[]P&".FSC@[_HGSX<HP\\^A]9VOJ@@]WD:5<^FLM@&!?[+/E!%W(IFP\
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M'O@H/%#+56(M.*#.DAC6^!MQ_R@,;2/: ^V!]L 7Z($&]B_PH/>0VP/M@?;
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MN2PG_=;Y]D![H#W0'OBP!QK8/^RCEF@/M ?: T\\((0:>09B =QW/[\YEJ8
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MH^U/^\<#P9)'QVX;;4=[T_,_=JIO7!K>'_O3'F@/?'H>N/OT3&Z+VP/M@?;
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M^!>&D<N\_53Y\6#QLO^$.MH$A&_KX[6)U'YR/%4?RV2HVR/L^/OA(LJ>D'U
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M.=K1_L_^T ?_R Q[L.VOZO?/'M<?H?_NCU#2.MH#[8&/WP-,Y$SHM01F@B*
M4) 0P%QEKK5.D)\RMDF0!1Z,_ G1F=)&>>6R;,_;UKY(!1/K2"D7:)2U'U-A
MG[2V>!C0[KUM[<\Q7=5IB]!D7[8C10;;2)4OV]^>@1RPYHTAE4Y('V647V^
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MEW[M&R 'IO8-2"\Y?RAJFUO0;/U,,U(ND.-W=9J_3!/\ [:5+=NW_DYU:6/
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MXT2]Y7DNVZYT5KN+Z_SBVGKN^L[^2O_\G0,P=VMIQ*=XCVR;GWH . :V 6U
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MCS8;]&?YD[SM)]!ZO 1:]ZN_U+N![RZGO/:34F;_1M>Y?ATG><K'-V9O0W[
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M>C)B'?"-'MN?\G,YR@GB(_J>LO:39?:9J7;97]F[]8],R1DIWQ\VZK^.CE=
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MM:@# (Q:ETT[\#X#\,@SH0O(Z#+"*&S[&CS\B]]*/G2B@_X/N.&?J$P? _S
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MUSW2G:]>-,)]2G]8470A>4]'=/V?XY\KY3KR ND$\66'.JKML<Y=@%]R94O
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MFR Z0/(#7X#R!EK^6C^"!)\?= !,8%>HNMA>,E\!RN7/_I1KCHSG0Z7N_=Z
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M &+90#:"4 2Q#&Q9EE<9'IM-XOC4)A\!SG&3[OW,*/+KH0;KZBM83W L*.^
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M*'7H"J#@#R (0*B,]T%VZ1-@^^I&@3F6+AO-_L7S\5V!T@9Z_Z7OXY[9[AT
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ML[=;7SSQP)4!#GX"EH&0>L %=7S6 -B.Z:,\@S+C4%?\F=&FK@,70<M.JU^
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MI?799Y=?8WQJS\Q@D_OOML _DP6>_IDF>\_UML!S%B!P&E ,2% #REVJX!\
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MV8"!^Y=;=I2 67/X]-\=K+?7.IH]I:_RH&V<9V@'3HY?_,_]:NGA;2PKH.T
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MKR5,5K_8?"@)BK8^754WO2WP;5O@Z=N>WCV[VP(O6X#,G@&&(&$0$EQ3QT?
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M,!@PH 8G@;-M&73D,^BD_+W._HY'\*5NYW/<:NMO2P!$$'0%%B5C@/,MFWT
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M*G!$,!) &Z"D&:3V,L?)1R!I 6CN>\\ M?<W@T0]GYTWCY%-<"7(%BC.H!P
M@SZ9.3=;N->C9^G>7Y?&_F7L4GW[#Y4D.)_ ;?X"9@7\3_/7%!.L+^/V#&?9
M)G0E"\R\ 9CK%I/OCF]768'S#L ;T&Z V#;J6GT#PZ?L]:QK?;=CP3-R1GEF
M[<UJE_Q\U_HR;@/Z"\@>LO(&H>FM'G5#X%:9>)AUD2-8[^"?/KF'G7/TV@_
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MZZ799CG;"(C69W_*!J)J[_JD'@1Y/O"I.[2. Y38+GV.QXPA>B%;4(XML1/
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MSCI\UCC&?X5O6W@W'PI?^8L7J+(7/\D<MGXF'+3-36\+?(L6>/H6)W7/Z;;
M<Q8@N\Z#;SC]"KH]R!A@I :?"HH1F 3?4H-*4MOVOO H7Q[J6O":>T'ED1J0
M#:B^'8/V$9@OP,4>L$>?#CHX+GF"D'J0:WW8U QZ!O/J-V0T --DO7P#4?/Y
M]/[AU8VG7P,=X/LATPT@WD"[6T2V3+- =]+GLM^/P-E^!9SC!F&"Y!6<"[ ;
MG3<;!:3M+W4.V_P<<X[QO%ZG&P#WL .,!99%3]ESM\MT\)F@TK)]H7YH WB.
M,<R<![6M^JN+[1Y?R*$/\EE[M=8/8#/7=+L>YDUCM65&/4%Z7#]#!M=#CG'1
M-Z^[TK%O9:DY1F;<N:<-3_:2CS:SQ?3!3]1UU7\$2]]&FSK87K3KG_.1[XK:
MC^M2'X-?TD?17GYJ .66<1_R\(_]1F'Z,VX@6C_ET+:T*_< PM/_VJ_Z=AVL
M*]VZWB08[K_; M^J!9Z^U8G=\[HM<&4!G/K'G]O>]3UX7 4)^ Q:!HKJNP4U
M^R</90.6--NSSC&00S"$6@<0&(!9<)W@(T!& @[ ^ BL'=0CDP_UR-QE$WP!
M$!D ^9I>?5;Y9X"SC*F^ 9  DQ.,"GBE*SA]:?N*8%6J7(&S]5+KY6MT FOK
MY6O]&LBGS?JUW+/Y(^L=_.Z-%YP+UG<:^^Y7V5.6NNT4G; 3VXNP+<><IP*3
M/7/+.148[L R :5]H%7N8-IC>$M6/$RY]W\X[B!V[P= 52XT^SD.]0+"L79S
M[<=ZOFIW/;KN<PWO-[4/O+%N1YLWJ_$,B'-Q#F;4LU[[R\/<J).WV6 ^%U+C
M];'@\P^9SM4;>'C)-@];J2/ZYXU'!_7.)=OHBP[IR\IFX9/H-]JW;P+3GV5Y
MR9*;B8]G=5(F97PDX^HKE;7K(A_ZM&\'[[WLKI&;?EL6>/JVIG//YK; \Q;@
M:V:<NL#3H&.PR "1@<#V[)>\5W((,F:9##P>G]I&G=MS>N8*^0.L'\ #^J%/
M!;,3#3!O<.85B@1F][]"^9J=<90'0,!F/-!50?PD^Z!/ZI%EY ((UCWK6Y;<
M3//[%1BO&><&[(_ 61"LG/X:Q0+  S@#@+TYV&1M_07Y.X#.^AW0*SOU$V#/
MNGF#D++DFY1M0#_\]N[#?Q0(I_]^W'B_+Z#.FW8 ['PH-P#8?FA'D C8&^6>
M&:9.X$A;E7OV&QG*@0I K<MC?]%3/L<IWL@\6[^/I2P!+,>Y)EV;TEI?"=YS
MK>_71;3ENASE:/<ZJ7&B?@'Z0WZ[*:XY1Z:=XYIWW"CEO-(FV+OX^SYR^WG=
M<\P--!^N58"Y0!W]/W[ZL<XI;7XCAN[-3G'3O@/WP3/]!V,A7W^'[RI9'6A;
M9ES]I/X-*KBV+H_I:Q]\(6,H;Z?*TF?"2YU\CJ],;?1\%+A;;PM\G19X^CK5
MOK6^+?#[+$"PPZGK] T(T/I$MF@/)/;9ZPT:&92RG&,0>)YK4P]E0AF/H,V'
M8S\$J6I/L )_'D=FNWBK3PO> (3]05.L"D '),E?@.KSIQ%D:_P ,/MX1[UZ
M%I(VWER28+3 :H!DCU_D&8 [P?<*\@7'.Z!>ZP7.+8MM&^./S/[0S[&^KX=$
M)V_NE5_E =Z3SWG-NN_Z Z>-C_K6-H\!WN\__J4 .#<[?*B#3CG>@*CC=]4.
MD.-\<KZE7 ,%R/O^<-^9WFC;,RXO ),UL -KUP6R^!1/YU5VMF4Y=6$<VJ#(
M4%;5]>.QIEB_N?:\!JYH70L!5I/O(,<U?Z*G.O6J:Z+?C.9<<F[6Y_SV^7(3
MK4PHU[S\WEASS>(3:LP^!_AHK^MW_,#5+[_QYI>1;0]@/L9(\!ZV,LM>H+W[
M(/JD+RM?U?UE^D1]&+X.'3V&P@=-'UAVC6TNC*.\[#MD]:S\SH=,]-4.OR]"
MW+UN"[Q="SR]7=5NS6X+_+$68.\Z8/04-*@S(&0@,'#LM *)@<.O=T<V? 8I
M,T/P*]\@U )5XW7,5K=FG C& )S2,0%XEC<@4W(2G/0R8(=@7#(!2I'-RT#G
MC8WZ&/31\TJV;5?M)2-^P51@WL#T8Y;]V?J^5[U =7\_^02N_KA1 [#*25Y!
M<]6-K'L"W@EZUWY;-CZR]R7SQW7LU(GVU*7XM^TUM /$.4\)R)73Z+P!\/@H
M^WT'[/&6&-91 <#(="_@.4 ]]0!*UD)=.P$$!:*"4/A8/UQ?\-*'.F7(UX[;
MZPG- @M::2N^34= +&L*FQ05>.;Z3_"=-ZSRNFXOVI:;3OHDD.UCN[Z+QGCC
M!J+7"79S[LY1F^0\M27]'"/G2CT?,]Z#I\^)-FZT^,/VCL4U3ADZ=(RY*6>G
M7K_H2%_\%3SX'WV7@!O>V>[#KRL_O/K!+,]^S=_5<?>AK3S!??7O-P>T.?Y>
M1D?F?/_=%O@6+?#T+4[JGM-M@9,% !$$T0P\F06BWL $)1A4L(R 9;V!JH);
M@OT.S)%5/#W(&&"LK[%BO I0,:9ZP3<"I\ E0 CZE XG&J!"/G7"#@ F@SGU
M!OBV!:;].$OV@R<#?XV[ Z #T'%,9 D\3UM&9EMDMMWS+1V9[@GP!;Z-"KKC
M;3+11QZ!<Z,-G%,>&77'6[+X:_8>6>JL/(^97\K.>O6ESFTK9,\YK@_;7_J6
MECI^_T-\(X&NIT_,-W0&]'-> 84"0P$=:\"ZO<R: P0*UNLE@SV#R[7%VD%.
M^[3]UM07?P?M/#B)#,=H,ML-0+VR,-K<)@)/?@"IKKN%;NN]UF*O&^4K0+_U
M=8T7S3ZGZVQ?WR>>OCV%>93=T\[]VP3GB]TY/^HP= ^Y->]^[8TR[:7+N^K/
MS1*V1A8^JUW+G)?VC6+> .08>3T[?W5QRQRR[%,^T6\C SB7/T.G\'_(27Y]
M('669[_PO9'<2!G*3IG4>:R.V#V3#Z=8<-?=%O@:+?#T-2I]ZWQ;X/=8 "<.
M !"$X^#+V9NY,6->@:=E=^0QL,!/&3J"3N>O@!$@G&"3 :7Z=EX#4>-IX%ZY
M8\SX2IPZ]ZN:_:-OC;F#B #JV5[\O0V@P+YT KH!F>#-G QX '=L=0SV,89Z
MU%@'G2HSR%:8^A73TR^7"K+7K':!^OYN<H!K>T_Y!.J"Y)5.$.U-P0#/&W#_
MSWB33)8%Q!.\I\P&EDN?!3BO<RB=XEN E%G;63[^I?:D \S=XC+U;3;BC3GV
M>Z1SO%47;Q1:._(YOP4>8V^U('J =X&D6>YZ4\G<8B' % BQ-G@(F74$>#<#
M3SN?O.F#Q_%I:]GWSU7G^+0CAX\\[9<_V8ZS;LF!=ZRY7(?].K#MBHYU*CC?
MKQ^N4=<Q5+Y>-_K#MXU)F^W:W3GNE'G \]Q8U=;'5_9.N49YZY7G%'MC8_ZP
M95W#G^9K*!] ^N4\V@/+ZI@^#S^1O@T]TT?J8^V3O-3YH1_EA_[I7WORHV3H
MJZ-]Z-+]-_;!UJ[!WQ,K[CZW!=ZB!9[>HE*W3K<%_@P+X,0KF&Y9( (!]14X
M>E:=NCV(&) $U@8=@Y/!9QQ'4$&> +_Z&7BVFX0<DW'8LD+ K* ;@1L^ [?E
M'3Q87W/>^)%I4(<2Y)T?-P;8ZACL=S!S"/:."^536QH^OOOMAP__]@! !9O2
M!-_6)9"==2N(GN#Z$<A>]9ER'_O,MC[. ,^3%Q[T=>P<9^GO Z.=<N/"/G[[
MK6!\E=_:6IWRI=E&>:UO8'_)L$>F5_ HR#L=^VI!@(^@&Q#M'^":>BA_@';6
MS)*9__67 N8"<M8://1S;-JX(4!.6Y/S+1^,W?JT;3F.LX#V?4UN -OKHJZ#
M#6#G6AW72=P$C+I7CJ$\^G'-HB<?YXJ=J^PU'0 _QTI0G?7.I<8)?\#UC.QF
MOWDNJ*>_-QV+K,TG%%]<S_3A9KML'=MAAM\+GY;^DG9D0=-7ZO]*A\\?AC^4
MASGI@TYCI%QE)5^3V\9&9VWA>KWI;8&OW0)/7_L$;OUO"[S& CCO%GA6($Z@
MF0#;3/?DJ: 3@<2 8G Q2.1Q!I:]3'^#F7WW,3Q&W]+Y$%@9K_I? )!C6V02
MF3/ *O^TD4"C0+QC)P@*0#/T4!]H\-:6AGC(- %Y@EI!:P.Q[8%.ZJ[Y3\#V
M*OM-??!'IKWDQ[%Z/ +@V;\!XS63G?WX)D"]X26#CDT SRM(1Z9R5WD#?%_H
MEOH-WI[Q'S;\\%UMK:F'3MT7;K;;-\+$<8)VSKT92M8%:X6UV,!Y ]0%O.M!
MT;E_6L!NWSKN#Z(BQSZN;:CC6@=/^VLW"EYSM/O'S0''KC76^U+>CEVGQ=>S
MS8-?X"O-OM;M- #\M<SVO(AS!*ACUW$#K@ROISZ&NBY4GEUW=/W4D@&,P_G!
M?F3<.>]-M^XK.J]RF7^5I>K3*: 8'O1%MKYKTIDI3P!MV?.&#N5G>V:=>GR<
M'_F2TH:<M=_<(S_[-CECS#Y'=,86K)/[[[; MV*!IV]E(O<\;@L\9P&<M]DF
MG#V!RL!!0*&N!9863&@W:!@<# K5/]YJ , =@:673\%'.<FO3/D=DV.")!EV
M@<4YN,97W5M +G[F&4!=&37G NU_78*:&4T 6NFYR2P;];H1\#F.H"\/_:F?
MH+0!Y[;]I)4%ME*![P2AN3=[9I%WH+T>[\"]9\+[PZD+;P!B=9AC-SGH;UNC
MO3[Z[@ :T"Q ;_+F@Z+.<<KJ\L<6&D'\G&_*7^TY=6QR9U^.R>0+V,WR AI9
M6QX+F*WGV"PYUQ2@9P7L[4IK0'[RFF$',%*FG>L.N=1Y7.NZ9]5/>IC%9RW2
MSGJJ]?7YPY(U14_76JZ_L>Y=NV/]OWN\%N1Y)1WCY745:W\?&[VX#FJ>O_RU
M,M8UGY?&VV[$EW&WOGPCQKCU 0Q_^N\"NV,<;S9"YUW/.M[F(4_I__]^7+83
M.A9T^+7(J.,/Y:GV[A>=A_YN]._?-,(+3\K41UI?,L8VF?G *GT8UW;6Q_UW
M6^!;LL#3MS29>RZW!:XL@/,65!L #"B-SDP[CE\>@X !9.TS,_*T9T"1?Y%#
MP.R9)>HMUQC5-C-/?_WYIY&)8TQD5R#*<@9ULW."DPS2A[[* T@ JO@ R@!6
MV(J;F].X@G_;KJA@G3W4 M0)-">H'.!X [\[^!0PIZRJLY^T,M93/OQCC+'G
M?+9GVYK]!@A/(.U8):_O?7_4J;V5!:!>[TS_R=<S"JH;;?V^^^T_U%GJ>$%S
MOI9SW$7_'W\8-Q;RNH<=<,YY%2!G>0!U?]BH9X)9"_ZQ/NC+&C%K23M]/_[<
M]['SL&F]LW]NR:!=\"\_L@#OO_Y?^]3:B[?6<,P?XS!FK=6>Z54^_:LMUCDW
MM_1E'#Z,V]XPTP M_+0['C;PF#;6,NMVK^>&!UD[+_P S^+_N8WIN)G=5J[/
MSP#BQ[6<9>0=KM6\YFH./[>Y,6Z^\UX0W*[M=_U&O[]99]BI'Q_&.H[=L_?H
M7CXA@#+CE.^*NK))MTN51YL _NQGRQX;R%]\9\_*.T?I.OZ4C3ST=;VXCF]Z
M6^!KML#3UZS\K?MM@9<L0-#/3!U!1#"=3M_@ (A.'NNE]&W!I8/KGCFR79G2
M'(NR?-9[[+C*)C#[C0!USV80MR!?^J-7!.7*PB7 KSYMCZJ@JL#7:<_K0[\.
M+"(C-_2+]ZTWL"XXWL#OV IR ,8"5H%L &1!]02J6_;;/LN[SQM0MH]TWD T
M'02YMDNIGV7GTV166\^F^_ HM/0<^]Y3/M\8^-:7J?OXUD']I<L\UBQ]Z33&
MF'I-7=LK(EE'G-M31AW0QUJSC;*? N<;  <H^U?@5)#?@3G[WJD'W-:Z^OSY
M-]\PPUB"=V0(IJ"TP<_8]/6/,GUH1S;7,\=Y;;#.Z8=NR!)8(X,R(%P>'K3V
M#SWG?.8/@Z&'?_3G6H;Z5W7]VD(7_KCY0$?EH<^\_M[]]NY_VJ_.UHWLX7HU
M$[^ ^>7Z;==<LT^[^=(NS:[8MMFWSG65ITWIA\VXD4"O99R\:<CR^(7D^2U!
M^C7+T@?_=O5\3B0W](/*D,[ZZ3/Q@U5_D&L]?K1\:+]IX!R[SCQ_-[TM\+5:
MX.EK5?S6^[; :RS0 GQ_AWEW^(!D 3(!PN  G0#ZPY(!?VCKLD80B?V9!$3X
M#3[0"B*Q;S/[56"/M\L06 FP[O^N )O!.X!R9M\$S6;#!CA(_@ +S)4^C ?0
M(+AE9A =_:B#8]1\0I9\.>8$Q&<P6< R@&D#O_ V_@D\)[ 55$_:>3NH+QE]
MZTOC<6SI!-IFJG<Z9<L[^\KK..C(C0EVX=6,ZIXRG(=4O5+6J2[Y&^^C/CE>
M\CM^9=CYX:0.@%0)NP  ( !)1$%4X%A7@O-!.U &\-'. Z %^OK^] +*_>%/
MKSF!\4D>=54?6V$ E]0!=KV)IJX 5;^I9ES6#WS^,4Y;FPV,TQ?=6+-MK34P
MB1S^D.D:%3Q35]?D]MP&]1]_G@]?,W]N;)&;?3GV&G$,KUGY!/9<Z]JQKHF/
M#:SS7 /K0_EU/2W@>%YK=6WE37*_?K,//.BE;F7O_LT(NK"M")M4>=STM!L?
M^GB]ELSP+0_'?F/7Q_-W&^#3KY7_C"TM65]Z+KYP9L'E@RI/FOZVY.,[^QB/
M,IL/M[Y\;]<OSYMKZJ:W!;Y6"SQ]K8K?>M\6>(T%"/@X[73F!@#!N6V ^+W-
MC(WU&0P,+E+E*!=>ZEX*2+:7[,\?"I",'XO90#%C(;/D;M0Z@ ^@P7G+#Y"1
M1U##,8$0?FQ%X&??LWS+#4$$=OJ? G_5L6]]9'[[ Y@#F+=L<P+0%6@V<#S;
M9V8>$#IY6_W,5@MF)Y578"RU_F%+RM!Q9K('[_A&8(X+&&;["QEU ?)*)]#/
M^B'SQ\?Y#)UB^T[I_=/4R6/G(YUCS''1CW4 .,_,*^=98,EZ*<#7 3MEVQ/4
M W!9(X!F0+S]Y2VZ;6T!T (:O0$06%/_UU\^%:CD.N88'M8W<K..-44]\AU?
MX$Y]@C)DN*89ES_&=#M*UB$O^Q;8[]>#>@KV=S[&12_Y'$==T:'>K?_3]Y5=
M)\/.6N7:\GI'AM?9:R@\X].OT7$<LE(N^O!!?^;KG*M?W,ASO%SKT9;R[%_S
MCRTLZ2=I8X[XL_2%99O(KF>;?92+/O2?/A29W5Z'YX=*_P#^L]^'Y1S5@KC_
MNRWPE5K@Z2O5^U;[ML"K+$! )5CIT!^"2 \*!@\I?"V(S,S."+01& PP)[FM
M_YX]:O+RYB#'05<^!#=T3F"=98-KS:OS.4?FG* *\,\8)2\"N\?,F4 ,.''<
MY+?LF!Y7_PCLU??PD"E <H#4 7RS3I"]9M)GGT?>;)OR&U#=V\Q"K^!^CK4#
MX E\UW?&"XP!ZK7MI?_0D?+I)X\Z[<=3]@35I_%K#G$#,?O%#8_MTH=O)N8O
MG7)^!_CN[USG.$%W'@OB[0<0=EVQMN@'/_7RI"SZPR\05S9U_%$/OP#:FT76
M$#+]0W9;I^T&,=O((M/.!YWX0R;\7(_*9BRO*>O0@W[4,W;K^[GZ<IW3AS_X
MN3YV/JZ!^FS;9>A7.M=K.QM89]TUP-X>H#;+[K6&ON/:BHRV==6^^8+E&NRZ
M(,\;$WP%XXR^P;/7I5_)MJ7<;Q"0SZ=\862]M864OIR#\J/;-XS9)D_Z7<O/
M^5O:E..85]0;S3JA]W^W!;YB"SQ]Q;K?JM\6>-8"#11\KN!B\#%  )@-#-9)
M][;JVX.30-O@0)]=CL<&'.424.G/I\ETJ\P$]0(+VM7Y69H!OF<ATRB $<")
M8*J! !](8XRYCWV.W=J9XZOUZ+QG4+P!\O$VE 8^!=@+<.T_F)1@6!"\@]<\
M+ED]N[_+E<_ZDC?VDZ\W!<ECO\JH \3\1=+W/\2[Y0'@[3/VH_N:Q66+SAQG
MCM%O'C;@7?KUOL_Q+G:+&R+ZCPQ[WR/N.DB@#< <]1W,4V<]H%4 RWH"  '
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M=D"<'W[27G"]4ZX=Z^ 'Z'B\MPGBS:9[G/S(L)_MU+GN<IT]5Z:-/GX>UFD
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M;&3 [<&QYD(YVS* &]BSW<!Z",+/R<FV&C?&0=\$L+,<&6%!=&1[,],LF!V
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MC^4F(?69Y=K#WG\XZ02R,Z,.X!6X4RZPWO>C6Z\,CW<^CKW9RW7Y[#K,=1\
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M9;>Z](RZH+W=/'D#L=($ZLY?>07RWW]7#P\#V N,]ZTN9M>I6][#'N]=EW^
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M[/<2S?&S;+\<Z[FR_#NU#U1?4C;<K^D\%\^UA>_8ST7ZDKUM.4[YFW]"1Y(
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M&1M0RA^R2N]^0P 0YX]@S;FRS5\N12;;/ #QUJWZQCOEXYL'YPL%K)>-Q[<
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MU9[UCB'-MBP+X+/./M+7ML&'/.QOYEJ;UWKU7%WX L_IZ'/A)\:MI;$  "
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ML=IYM0OSFG.BK^W2)B]YSF5T!23M^]<%Z.Y9EV);;)AKR?6RT\;K#R&U_=2
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M >G.)\66FS(?3>D6F'HJ#-\#\9GK\;[C/<2+K2H-)+[>59_ 47!_I@DZ]=W
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MZTT%/%_X9"S-L5TN=4OV#.R''_T]T"S .6:-[+"[7]O.;779 ><=H _^!(N
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M34\!W_[%T_T9Z WH?U.@'AE@P%B:S'GW<YK\W%[#N@"R =Z ].:C_9*J +]
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M-O@I7](L? &R2S<*G+8+S6*8MMWG,H_S03>_!=C9FE' &( 8OUYZ ($G()^
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M FY\^73U/VT 372VH<;>SJ7[ZO-<V>_GO7RJ,6ZH5E]E,VX&[*ZO>]<%=<^
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M<G00C4_S;-$MI\(S9ZOKL?KDYWJ5S]999QYXJ:N]LG'<Y[P!^\=4XUOW2Z_
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MIXU;K&W/_;,;AQGK]#=C2E[Z=0Q%IVX. A0GT+L:GX"?8%Q9VIYXR)_9[/8
M8%X#L/_K7W5M%##NH)AK!:#$'P = ,[<@&T[[,C0X;W-'+S0FZ"\ 6^._=ME
MV-"-YX:!.5NLS8XQ\^4+WNEU6I<3K_F?/DXZ\J[H[B/7GC4DWLI)^;L/<:V/
M7&">Z;GG@4\>R7QQ.MYR#GD$/\/7DM=\JE7;SL?_GU?I]AS:QC-WFE>ER!F;
MSY-FSE4_>=5%W[[?5.N4N;H#><^#F\(;K'OUW/2]K<#+>POHCN=>@==6@ ).
MP3799[(VP5.,6\)N"=]$7EUX/TZ-9$TB;_XF0->70%P?4&7[F&->51CL>EDH
ML[ %SV)1\V>A78I?_PAW]Y'Z^-R/]X(:\S(?!5J *)W@MP'+!+2 Q03U@(SE
MN+K.'9!^F"!T^FQ N-FT\9QW/2Y^]P$XW?4:@!58S[F:7@!F]X>/CG@ YMZ5
MSW-P+!4@S_D>;P12EP[[>B,TUZSIS5C3YQP_GA,R;1GCG^\?))@3\)UX*3O)
MX5WQM;VB:9=C]>4)V-GZPO7;^ UP)BA'3QF48\$\N8$./: >'^L<S1?;8/P3
ML.L/@,M['I]<=XW?@#]?%&<>OQ3K'';SG>N*XDLPK5]HCG?;79ZZ5V-]-/G<
M$L/YF$NDE5/, 1L85R=SQHF7/E+W(5_M\T?^(H>RYN9M\V3F5G.I.5I9'5]T
MVENN?6S<5&SQB2OG98YW[F:[-F)X#]Q;8KQZ;OK>5N#EO05TQW.OP&LK0"$E
M^9*$2;HF=BD\$G;*&/M23Q_0DED4(M%K ]6.\6X[9-XH]"^?VF5?.E<)JK<B
MNA3'9^ \[$XVRWP=F ^]M.4)(]__]]*=+F"X;=688#E_5$A@.0'L!)T3% /6
M!;3I!^ Q]?&5-OIN7SQM #A ^-9I/]E.@+OZS1CF_+''WG.71ES3-A[9./1:
MS #V_8DQTRYCF>MR6I^,;9Y?_\2A_[+I"MY6<+B#076E"0CE25/VEK%V4FT
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MK^6GSZ<>-X[WEABOTIN^MQ5X>6\!W?'<*_#:"E#H*V&/I#V!LPF;9,S+1)^
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MND#J-%]V?5IGCA@+$//Q\0Z^L_"E+ OI7A33IA?#I<#N-P0'?8NI'V&[I[3
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MS(7>H\Z,I?EIH+OICM@??B7V KS'7*R;W75!6M*KL8!/^E:]D[X\:?IZG=<
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M7UB!E_\+)W&?P[T"5RL 8.?YNQ0B.^"5[/MQ*P;S6>P6C5F$UFZY16 4BEZ
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M\_WQ0_^1(H&P +P!93O2@F&.'\:"Y@&F\X>/5C^[O>#;>3Q^ -W9:7>^_HE
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M7;DLIN5_+^1Y;!%^2_?=@M[MR[>\3A_FT[\ (H[3GIB7[2@=X$X@/,%\\0(
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MYM=JO8[SNNS7_94?=,T'#^P1NVRK.<T'/WG]"OQJM5KWN[BFDW(/J_?-R#7
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M+VHOG;B&\U.R?FWZM5< =5PG+M?U4H_MNI/^=&T]H-MS\'N%V4CN.O+-ZCK
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M>#<@'6-6OZ$=G+.*GF!] >(!_C,07ZVB#U#/RKX>)&0W_JII^Z48!W5U[,>
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MCQ.Y:JLX &H .D!;%-D\=H ]=(9N _'CN.V-K\>LS,,GOJAX G!:81=(]!?
M[HS> RJQ==W'\M"'NJ^SL>NZ#GSH2B8> !L]J.O?,\:NTFI+/.=7FX>.W?9L
M/'R,!S.=FYRC<:_0.7]Q/9R=\W&]F9W[\#$/P^''] ]^\WKMURC7E]OX-6V
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M>'R,BZT:BQK2U(S48&U%?>G?@#H-#3U\BOI8,=7 ^*4''<LF[!@;T'YP9<^
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M6/H)Q]9L\>\-=Q6WVQL Z+S\(S8?/WUL^VD[\$R =P9"I&<@Y@S<M&9>P>(
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M?<[7&=?R?.TV^R&+:S+CD\O\$#!_N72.,7R3%Q0]^=1UO'\1Y@4TFIWBJZC
M[57,8D]B5^ %5X#?:%>C#K"0#5X-4<V11J\Q+^<Q9B7,&VKH QYDSPJ<@6O9
M 1+P3_,?^F9K*X4T<>S)9?8S0 ?\T,\OY^F+:JRVKP"<8D1=SF@!E9,^0#1M
M5WZ"YV#7QR6FZT8<!WT^=H!7QIX#X"_F;?9]#F5N;HO.BH>LYL@G!/!7ML%;
MU&!Z:+"Z3+'$]WF4_ ^ZYN>0B_GILO)^XJ_+TY\?3SH/Y#/51^^;ZUMLO5\"
MZ+_]\3$HYZUBZ1Q7?,YU71-<R_"X5@'07#>R=UD]CGG9=2Q_3<>N3WL84%[N
M;^@?KWG):AZNSUA4>6RP_H*;SD[]15;@]B*SWDGO"KRR"OS^^?>^KYN&2#./
M1FG-5,?PIG$"\]:D;97/5NL $JWQ&Y!.V\ZWIC]X/%#,JV\ME_&'701.:/R2
M,=9\PE<!-:RVL[<]\@=X&6@3, '@,@[J@+CJ(W.^@S#D9]3M"KAD+J<46P-Z
M$YA=^#OUI?PR[]C.4^<0Q_-*>ZT-QY<Q2D[85/HD'^3O*^#4*-_;99PZUYJC
MRU?^C'?P;S+-J6^5JOP\EKW.5[:_:,SU)AG7@L9^_?IUP/40N@;LJ^WDP[:S
M*4_IQGO0K],!P+%KM.E)GSQ%X]BN37Q5_NRK7>/2U;SW+\*\LB:TI_/#5^#V
MPV>X$]P5>",5T/88K=K1T-4LU4 YUM@;*WRH9$.GC%E9#R QK\9AY\U9?CCV
M,3G1]-&!XDLVY*7QY,-6"*4?-KG:KBTR '?Y1 Y8A?<0E5VU"9[[S#%Z75[
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M')L_]/ IN?S5>P/RKC_EL?[T;:^LO_$&M:?_72MP^Z[1=_!=@5V!0P7T):X
M!;G*I89*LPW*JAI;3!8K:#1S]+$'"$Q\_&7##@!P,FY@HZT8.U"@^8L"(@ "
M30_0,!X.\$4\J$"0__*&:B&@H-QE ]B+L?(LX OP%_X3O,6XZIFOZF.E[[P^
M=C!YXK_ZUG'EW>/OL!7&8G?[?+ )_TOY,3;UJCE-Q^:K^D9O LVU%H!H*/*S
M]Z?&0]_I"0@?M9A7^,F[RSV&Y<'Y%4 ]/O'1IS[M%XTX!^5++YVS?I[W<Q@
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M 1X)"FBXWM"]V6K,2[IJS"ZG23L/_28;0 5=!R4!+HAAJW8>"WV 2/AG5<]
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ME]+.:%=@5^"J OQ%5#5:;[J,'1BPDB8>X];8CP!DDB<8QJ>HR^7#XUR-W4Y
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M!>17H%P@6S*]*N".O>X?/HPM,;^W+Y]*5X!=__1 H&TPBL<>>>)NNBOPW!4
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M]!NT?Y]SX;5'U;DNX ,H: !B@('IN -6/NX' (W52  ,=@(%@!-DE3;=HP^
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M+BD'F)/_R&O$A(</^8VXU*70D-LG#),=@,R M.;&_!RX"[P"8H-^:K] XWP
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MYH(L=)FGQ?4ZD#<\I[*77^>A3^TEZWKYDY( Y@:4/\5V&M]:PQ:3OE_^T\<
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MV<./'.R<<QDZ3D/N-<GSA'E77>E[_LR)N!S+#M_ZY$1@70M2^]^NP*[ ZZ[
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MQ/'7HHIS#U@7<-=>=CU@!(A*P BX 0P=P)2MDCI "J!E(*H#P[**BW]L)_\
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MY?P(N9V#Q&2>02U7_+1?@-E _4ON5]MV5^ U5N#V&B=U-B>!#KW>O7O7@;!
ML:]>2ZYC_32>0+*.O_2??,B7'@X4V^-=^19HY]<ZM.I_]D_^]"  8-\?GYY5
M:O._M )Z^-2?JA>H$%@1"&G QE8AV?Z2X%TZ5\ (0 1 @\I&+P$;8CD <[^
M(4 6X,?U ;3HDA.T\H?M (RALUBU%M_]M+P'P"5VI_F@T/3:0X;;'VK2'RR&
M3\7L\US4'&!8Y^5Q/._*5PZ2]YP-?/;\R M=>\]5O_I^]'S+@QVZS$FYNRW@
MEKET/P:2?2[X$64>G%?HN<\S?]B,<V&N_UR;<0T00S1>^<>NF">QB2L=R=BK
M_J77Z;;?%=@5>'T5N+V^*3T\(P"NOLPFH.L 6N!:'T,*8&M%\;G^"40KSF/
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MD_<>'A3=ZD/'DKE>RW74=2T?[UV5NZ^KL7+U<T5Q!=3UX/N<BT-/NY:WU:[
MKL"/7H';CY[@U\I/P!@P+" +^ 9L.^AU7=EHU5M 7\!9>EH5T5@/  +7&@N
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M;1W0+V@$X#+@#MAJ(&D&S  J!UVL.@.R (P.Y+ #< $"71=> +()/(\<B!5
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?D( $)" !":PG\#]!127]Y9A6J@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
